付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1401, Subject ID=365078, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=22									
365078	Safety Follow-up	35	Metastases to central nervous system	1.71 Weeks		Y	N	N/A	Resolved
	Extended Safety Follow-up	70	Pneumonia	2.29 Weeks		Y	N	N/A	Resolved
		71	Pulmonary embolism	Continuing		Y	N	N/A	Not Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=361277, Gender=F, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=65									
361277	Treatment Cycle 2	34	Diarrhoea	2.29 Weeks		Y	Y	Interrupted	Resolved
	Safety Follow-up	76	Enterocolitis	3.43 Weeks		Y	Y	Discontinued	Resolved
		80	Urinary tract infection	1.15 Months		Y	N	N/A	Resolved
	Extended Safety Follow-up	100	Respiratory tract infection	1 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=366455, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=45									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1502, Subject ID=366455, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=45									
366455	Safety Follow-up	52	Sepsis	2.86 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=369073, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=22									
369073	Treatment Cycle 1	21	Alanine aminotransferase increased	2.04 Months		Y	Y	Discontinued	Resolved
		21	Aspartate aminotransferase increased	1.18 Months		Y	Y	Discontinued	Resolved
	Extended Safety Follow-up	83	Hepatotoxicity	1.57 Weeks		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1503, Subject ID=363422, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=66									
363422	Treatment Cycle 2	26	Brain oedema	2.71 Weeks		Y	N	None	Resolved
	Treatment Cycle 3	53	General physical health deterioration	1 Weeks		Y	N	None	Resolved

Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1504, Subject ID=364386, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=64									
364386	Treatment Cycle 4	64	Renal failure	3.29 Weeks		Y	Y	None	Resolved
Trial Number=3475-006, Site Number=1506, Subject ID=362963, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=43									
362963	Safety Follow-up	61	Tumour haemorrhage	1.14 Weeks		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=1601, Subject ID=360029, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=44									
360029	Treatment Cycle 1	14	Cystitis	5 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1601, Subject ID=363241, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=43									
363241	Safety Follow-up	52	Colitis	1.43 Weeks		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1700, Subject ID=365778, Gender=M, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=1									
365778	Safety Follow-up	24	Colitis	2.71 Weeks		Y	Y	None	Resolved

Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1700, Subject ID=367140, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=43									
367140	Treatment Cycle 3	43	Hypopituitarism	1.54 Months		Y	Y	Discontinued	Sequelae
Trial Number=3475-006, Site Number=1700, Subject ID=367898, Gender=M, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=22									
367898	Safety Follow-up	26	Autoimmune hepatitis	2.57 Weeks		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1700, Subject ID=368071, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=25									
368071	Treatment Cycle 2	25	Colitis	2.1 Months		Y	Y	Discontinued	Sequelae
Trial Number=3475-006, Site Number=1700, Subject ID=368192, Gender=M, Race=White, Age=35 Years, Rel Day of Study Medication Discontinuance†=1									
368192	Safety Follow-up	16	Colitis	2 Weeks		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1703, Subject ID=361155, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=22									
361155	Safety Follow-up	37 46	Sepsis Tubulointerstitial nephritis	1.43 Weeks 1.97 Months		Y Y	N N	Interrupted Discontinued	Resolved Sequelae

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1705, Subject ID=361850, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=64									
361850	Extended Safety Follow-up	107	Uveitis	2.1 Months		Y	Y	N/A	Sequelae
Trial Number=3475-006, Site Number=1706, Subject ID=362616, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=44									
362616	Safety Follow-up	46	Diarrhoea	3.61 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1708, Subject ID=364462, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=64									
364462	Safety Follow-up	74	Death	23 Hours		Y	Y	N/A	Fatal
Trial Number=3475-006, Site Number=1708, Subject ID=367184, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=92									
367184	Treatment Cycle 2 Safety Follow-up	28 98	Diarrhoea Pneumonia	2.57 Weeks 1.45 Months		Y Y	Y N	None N/A	Resolved Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=360234, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=41									

Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1710, Subject ID=360234, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=41									
360234	Treatment Cycle 2	32	Tumour haemorrhage	4.04 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=361645, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=63									
361645	Treatment Cycle 3	59	Colitis	4.3 Months		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1711, Subject ID=363265, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=64									
363265	Safety Follow-up	81	Hydronephrosis	3.29 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1810, Subject ID=364692, Gender=M, Race=Asian, Age=63 Years, Rel Day of Study Medication Discontinuance†=21									
364692	Safety Follow-up	26	Renal failure	Unknown		Y	N	N/A	Unknown
Trial Number=3475-006, Site Number=1810, Subject ID=366487, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=42									
366487	Extended Safety Follow-up	99	Confusional state	Continuing		Y	N	N/A	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1810, Subject ID=367702, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=22									
367702	Safety Follow-up	40	Colitis	5 Days		Y	Y	Interrupted	Resolved
		52	Colitis	4 Days		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1810, Subject ID=368904, Gender=F, Race=White, Age=86 Years, Rel Day of Study Medication Discontinuance†=64									
368904	Treatment Cycle 3	47	Transient ischaemic attack	2 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1812, Subject ID=360032, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=1									
360032	Safety Follow-up	15	Colitis	1.35 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1812, Subject ID=363484, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=43									
363484	Treatment Cycle 1	15	Clostridium difficile colitis	4.14 Weeks		Y	N	None	Resolved
	Safety Follow-up	46	Colitis	2.69 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1814, Subject ID=363332, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=64									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1814, Subject ID=363332, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=64									
363332	Treatment Cycle 3	63	Colitis	1.35 Months		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1814, Subject ID=368094, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=64									
368094	Treatment Cycle 2	41	Squamous cell carcinoma	23 Hours		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1815, Subject ID=360224, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=1									
360224	Safety Follow-up	4	Mental status changes	1.05 Months		Y	N	None	Resolved
	Extended Safety Follow-up	46	Mental status changes	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1816, Subject ID=361035, Gender=F, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=20									
361035	Safety Follow-up	34	Bile duct obstruction	2.14 Weeks		Y	N	Discontinued	Resolved
		34	Cholangitis	2.14 Weeks		Y	N	Discontinued	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1819, Subject ID=364855, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=85									
364855	Treatment Cycle 2	27	Colitis	3.71 Weeks		Y	Y	None	Resolved
	Safety Follow-up	93	Colitis	1 Weeks		Y	Y	N/A	Sequelae
Trial Number=3475-006, Site Number=1820, Subject ID=365324, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=22									
365324	Treatment Cycle 1	11	Brain oedema	1.14 Weeks		Y	N	None	Resolved
		11	Gastrointestinal haemorrhage	1.14 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1823, Subject ID=361780, Gender=M, Race=White, Age=41 Years, Rel Day of Study Medication Discontinuance†=65									
361780	Safety Follow-up	68	Diarrhoea	2 Days		Y	Y	None	Resolved
Trial Number=3475-006, Site Number=1824, Subject ID=361505, Gender=M, Race=White, Age=29 Years, Rel Day of Study Medication Discontinuance†=21									
361505	Treatment Cycle 2	21	Pain in extremity	2.43 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1824, Subject ID=361753, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=42									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1824, Subject ID=361753, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=42									
361753	Safety Follow-up	53	Diarrhoea	5 Days		Y	Y	Discontinued	Resolved
		56	Colitis	3.22 Months		Y	Y	Discontinued	Resolved
	Extended Safety Follow-up	98	Chest pain	3 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1825, Subject ID=368228, Gender=M, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=22									
368228	Treatment Cycle 2	22	Pneumonitis	3.29 Weeks		Y	Y	None	Resolved
	Extended Safety Follow-up	55	Pneumonia	6 Days		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=1900, Subject ID=362908, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=64									
362908	Safety Follow-up	78	Myelitis	Continuing		Y	Y	N/A	Not Resolved
Trial Number=3475-006, Site Number=1900, Subject ID=364341, Gender=F, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=32									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
Control									
Trial Number=3475-006, Site Number=1900, Subject ID=364341, Gender=F, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=32									
364341	Safety Follow-up	37	Drug eruption	2 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1900, Subject ID=364587, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=1									
364587	Safety Follow-up	8	Colitis	1.18 Months		Y	Y	Discontinued	Resolved
	Extended Safety Follow-up	47	Large intestine perforation	5.52 Months		Y	Y	N/A	Sequelae
Trial Number=3475-006, Site Number=1901, Subject ID=369394, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=85									
369394	Treatment Cycle 3	64	Abdominal pain	2.14 Weeks		Y	Y	Interrupted	Resolved
		64	Pyrexia	2.14 Weeks		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1902, Subject ID=365403, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=66									
365403	Safety Follow-up	67	Colitis	1.97 Months		Y	Y	N/A	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0001, Subject ID=362146, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=182									
362146	Safety Follow-up	193	Death	23 Hours		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=0001, Subject ID=365784, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=127									
365784	Treatment Cycle 5	69	Glaucoma	1.57 Weeks		Y	N	None	Sequelae
Trial Number=3475-006, Site Number=0001, Subject ID=368185, Gender=F, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=279									
368185	Treatment Cycle 4 Treatment Cycle 10	54 194	Autoimmune hepatitis Anaemia	4.29 Weeks Continuing		Y Y	Y N	Reduced Interrupted	Resolved Not Resolved
Trial Number=3475-006, Site Number=0002, Subject ID=361797, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=15									
361797	Safety Follow-up	18	Lichen planus	Continuing		Y	Y	Interrupted	Resolving
Trial Number=3475-006, Site Number=0003, Subject ID=362318, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=									
362318	Treatment Cycle 10	131	Hypopituitarism	1.71 Weeks		Y	Y	Interrupted	Sequelae

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0004, Subject ID=361690, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=1									
361690	Safety Follow-up	4	Metastases to central nervous system	1 Weeks		Y	N	None	Sequelae
Trial Number=3475-006, Site Number=0005, Subject ID=360015, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=43									
360015	Treatment Cycle 2	29	Hyponatraemia	1.14 Weeks		Y	N	N/A	Resolved
	Safety Follow-up	57	Hypoxia	11 Hours		Y	N	N/A	Fatal
Trial Number=3475-006, Site Number=0005, Subject ID=366940, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
366940	Treatment Cycle 3	40	Hepatitis	4.7 Months		Y	Y	Interrupted	Resolved
		70	Aortic stenosis	11.2 Months		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0007, Subject ID=360582, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†–									
360582	Treatment Cycle 12	159	Gastroenteritis	3 Days		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0101, Subject ID=361468, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=91									
361468	Treatment Cycle 1	13	Vein disorder	1 Weeks		Y	N	None	Resolved
		14	Bronchitis	Continuing		Y	N	Interrupted	Not Resolved
	Treatment Cycle 6	83	Pericardial effusion	Continuing		Y	N	None	Not Resolved
	Treatment Cycle 7	91	Myocardial infarction	1.65 Hours		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=0101, Subject ID=362772, Gender=M, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=									
362772	Treatment Cycle 3	30	Myalgia	6.9 Months		Y	Y	None	Sequelae
Trial Number=3475-006, Site Number=0102, Subject ID=362687, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†–									
362687	Treatment Cycle 11	140	Desmoplastic melanoma	1.48 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0102, Subject ID=362910, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=12									
362910	Safety Follow-up	38	Lymphangiosis carcinomatosa	1.28 Months		Y	N	Discontinued	Fatal

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0102, Subject ID=364052, Gender=M, Race=White, Age=29 Years, Rel Day of Study Medication Discontinuance†=141									
364052	Treatment Cycle 1	2	Cerebral haemorrhage	1.14 Weeks		Y	N	None	Resolved
	Treatment Cycle 4	57	Liver function test abnormal	2.29 Weeks		Y	Y	Interrupted	Resolved
	Safety Follow-up	151	Pathological fracture	6 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0300, Subject ID=366627, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=									
366627	Treatment Cycle 12	175	Squamous cell carcinoma	2.14 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0301, Subject ID=362932, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†–									
362932	Treatment Cycle 6	78	Colitis	17.05 Hours		Y	Y	None	Resolved
Trial Number=3475-006, Site Number=0312, Subject ID=362979, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=210									
362979	Treatment Cycle 10	176	Diarrhoea	6 Days		Y	Y	N/A	Resolved
		176	Urinary retention	1.14 Weeks		Y	N	N/A	Resolved
		178	Intestinal obstruction	1 Weeks		Y	N	N/A	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0400, Subject ID=368404, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=57									
368404	Safety Follow-up	66	Gastrointestinal carcinoma	Continuing		Y	N	N/A	Not Resolved
Trial Number=3475-006, Site Number=0400, Subject ID=368758, Gender=M, Race=White, Age=45 Years, Rel Day of Study Medication Discontinuance†=57									
368758	Safety Follow-up	71	Stomatitis necrotising	1.05 Months		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=0403, Subject ID=360347, Gender=M, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=86									
360347	Safety Follow-up	97	Encephalitis	1.43 Weeks		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0501, Subject ID=368971, Gender=F, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=1									
368971	Safety Follow-up	4	Metastatic malignant melanoma	4.14 Weeks		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=0504, Subject ID=361989, Gender=F, Race=Multiple, Age=69 Years, Rel Day of Study Medication Discontinuance†=42									
361989	Safety Follow-up	45 50	Haemorrhagic stroke Facial bones fracture	1.38 Months 1.14 Weeks		Y Y	Y N	None Discontinued	Fatal Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0504, Subject ID=361989, Gender=F, Race=Multiple, Age=69 Years, Rel Day of Study Medication Discontinuance†=42									
361989	Safety Follow-up	60	Escherichia bacteraemia	2 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=0600, Subject ID=368594, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=									
368594	Treatment Cycle 5	56	Pulmonary embolism	30 Minutes		Y	N	Interrupted	Resolved
	Treatment Cycle 15	199	Renal failure chronic	2.14 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360713, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=153									
360713	Treatment Cycle 9	125	Colitis	2.5 Months		Y	Y	Discontinued	Resolved
	Treatment Cycle 11	153	Hypokalaemia	1.18 Months		Y	Y	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=361127, Gender=F, Race=White, Age=46 Years, Rel Day of Study Medication Discontinuance†=155									
361127	Extended Safety Follow-up	202	Diarrhoea	1.14 Weeks		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0605, Subject ID=362398, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=43									
362398	Treatment Cycle 2	14	Anaemia	Continuing		Y	Y	Interrupted	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362624, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=155									
362624	Extended Safety Follow-up	190	Convulsion	2 Days		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362886, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=43									
362886	Treatment Cycle 2	29	Renal failure acute	1.57 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362930, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=85									
362930	Safety Follow-up	87	Colitis	1.12 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=364326, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=252									
364326	Treatment Cycle 11	141	Basosquamous carcinoma	24 Hours		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0605, Subject ID=367617, Gender=M, Race=White, Age=86 Years, Rel Day of Study Medication Discontinuance†–									
367617	Treatment Cycle 6 Treatment Cycle 20	73 278	Squamous cell carcinoma Malaise	1.38 Months 3 Days		Y Y	N N	None Interrupted	Resolved Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=360096, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=126									
360096	Extended Safety Follow-up	166	Rash	4.14 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=360678, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=27									
360678	Treatment Cycle 3	27	Hypokalaemia	3 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=368290, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=85									
368290	Treatment Cycle 2	16	Cough	3.65 Months		Y	Y	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=368616, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0611, Subject ID=368616, Gender=F, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†–									
368616	Treatment Cycle 9	124	Sciatica	1.48 Months		Y	N	None	Resolved
	Treatment Cycle 11	147	Blood corticotrophin decreased	Continuing		Y	Y	Interrupted	Not Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=360425, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=88									
360425	Treatment Cycle 4	58	Generalised oedema	Continuing		Y	N	Interrupted	Not Resolved
	Treatment Cycle 5	73	Hypoalbuminaemia	Continuing		Y	Y	Interrupted	Not Resolved
Trial Number=3475-006, Site Number=0700, Subject ID=363097, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†–									
363097	Treatment Cycle 13	169	Diarrhoea	2.57 Weeks		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0700, Subject ID=365186, Gender=F, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=65									
365186	Treatment Cycle 1	14	Diarrhoea	1.18 Months		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0702, Subject ID=365600, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=85									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0702, Subject ID=365600, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=85									
365600	Treatment Cycle 4	52	Metastatic malignant melanoma	2.23 Months		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0704, Subject ID=360742, Gender=F, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=154									
360742	Treatment Cycle 6	83	Adrenal insufficiency	Continuing		Y	Y	Interrupted	Not Resolved
	Treatment Cycle 7	129	Cardiac failure	1.14 Weeks		Y	N	None	Resolved
	Safety Follow-up	162	Epilepsy	3 Days		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0704, Subject ID=366882, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=144									
366882	Safety Follow-up	158	Adrenal insufficiency	Continuing		Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=0706, Subject ID=369101, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=									
369101	Treatment Cycle 2	23	Diarrhoea	3.43 Weeks		Y	Y	Interrupted	Resolved
	Treatment Cycle 12	201	Anal fistula	Continuing		Y	N	None	Resolving

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=0900, Subject ID=363971, Gender=M, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=97									
363971	Safety Follow-up	122	General physical health deterioration	1.71 Weeks		Y	N	None	Resolving
Trial Number=3475-006, Site Number=0901, Subject ID=362011, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance†=29									
362011	Treatment Cycle 1	9	Joint injury	2 Days		Y	N	None	Resolved
	Safety Follow-up	37	Diabetic ketoacidosis	2 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0901, Subject ID=368897, Gender=M, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=									
368897	Treatment Cycle 1	14	Intestinal obstruction	3 Days		Y	N	None	Resolved
	Treatment Cycle 4	64	Intestinal obstruction	4 Days		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=360434, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=154									
360434	Treatment Cycle 2	16	Abdominal pain lower	3 Days		Y	N	None	Resolved
	Treatment Cycle 6	70	Adenocarcinoma gastric	3.84 Months		Y	N	None	Fatal

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1201, Subject ID=368842, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=44									
368842	Extended Safety Follow-up	102	Meningitis	1.43 Weeks		Y	Y	N/A	Resolved
		102	Peripheral motor neuropathy	3.09 Months		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1301, Subject ID=367236, Gender=F, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=183									
367236	Safety Follow-up	197	Superior vena cava occlusion	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1301, Subject ID=368724, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=204									
368724	Treatment Cycle 14	184	Gout	Continuing		Y	N	Discontinued	Not Resolved
	Safety Follow-up	229	Sepsis	Continuing		Y	N	N/A	Not Resolved
		231	Cholecystitis	Continuing		Y	N	N/A	Not Resolved
Trial Number=3475-006, Site Number=1400, Subject ID=363328, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=43									
363328	Treatment Cycle 3	35	Deep vein thrombosis	Continuing		Y	N	None	Resolving

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1401, Subject ID=361560, Gender=F, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=355									
361560	Treatment Cycle 8	106	Diarrhoea	3.29 Weeks		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=1402, Subject ID=361567, Gender=F, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=43									
361567	Safety Follow-up	58	Intracranial tumour haemorrhage	Continuing		Y	N	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1500, Subject ID=362525, Gender=F, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=106									
362525	Treatment Cycle 4	57	Bronchospasm	2 Days		Y	N	None	Resolved
		64	Bronchospasm	2 Days		Y	N	None	Resolved
	Extended Safety Follow-up	170	Hip fracture	2.76 Months		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=360464, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=15									
360464	Safety Follow-up	29	General physical health deterioration	Continuing		Y	N	Discontinued	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1506, Subject ID=360282, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=42									
360282	Treatment Cycle 3 Safety Follow-up Extended Safety Follow-up	39 65 86	Urinary tract infection Pyrexia Pyrexia	2 Days 1.86 Weeks 6 Days		Y Y Y	N N N	None None N/A	Resolved Resolved Resolved
Trial Number=3475-006, Site Number=1600, Subject ID=368466, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=14									
368466	Treatment Cycle 2	14	Drug hypersensitivity	2.33 Hours		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1700, Subject ID=365574, Gender=M, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=									
365574	Treatment Cycle 2	15	Thyroiditis	Continuing		Y	Y	Interrupted	Not Resolved
Trial Number=3475-006, Site Number=1703, Subject ID=361701, Gender=F, Race=Asian, Age=42 Years, Rel Day of Study Medication Discontinuance†=41									
361701	Treatment Cycle 2 Safety Follow-up	14 54	Abdominal pain Alanine aminotransferase increased	3 Days 1.02 Months		Y Y	N N	None Interrupted	Resolved Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1703, Subject ID=361701, Gender=F, Race=Asian, Age=42 Years, Rel Day of Study Medication Discontinuance†=41									
361701	Safety Follow-up	54	Aspartate aminotransferase increased	1.02 Months		Y	N	Interrupted	Resolved
		58	Hyperbilirubinaemia	3.86 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1705, Subject ID=365415, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=197									
365415	Treatment Cycle 2	26	Pneumonia	4 Days		Y	N	None	Resolved
	Safety Follow-up	204	Colitis	Continuing		Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1705, Subject ID=366776, Gender=F, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=29									
366776	Treatment Cycle 1	2	Haemoptysis	23 Hours		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1705, Subject ID=367425, Gender=M, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†–									
367425	Treatment Cycle 14	187	Diarrhoea	Continuing		Y	Y	Interrupted	Resolving

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1708, Subject ID=367582, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=337									
367582	Treatment Cycle 5	59	Diarrhoea	2 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=364232, Gender=F, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=121									
364232	Treatment Cycle 2	29	Pneumonitis	4.14 Weeks		Y	Y	Interrupted	Resolved
	Treatment Cycle 3	61	Spinal cord compression	2.57 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=364567, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=113									
364567	Safety Follow-up	116	Autoimmune pancreatitis	3.86 Weeks		Y	Y	Discontinued	Sequelae
	Extended Safety Follow-up	173	Liver abscess	2.96 Months		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=366818, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=78									
366818	Treatment Cycle 2	17	Pathological fracture	Continuing		Y	N	Interrupted	Resolving
	Safety Follow-up	90	Pain in extremity	5 Days		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1710, Subject ID=367774, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=113									
367774	Extended Safety Follow-up	199	Diarrhoea	3.57 Weeks		Y	Y	N/A	Resolved
		199	Pyrexia	3.57 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=367971, Gender=F, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=123									
367971	Safety Follow-up	151	Abdominal distension	1.31 Months		Y	N	N/A	Resolved
		151	Bacterial sepsis	1.31 Months		Y	Y	N/A	Resolved
		151	Diarrhoea	1.31 Months		Y	Y	N/A	Resolved
		151	Hypotension	1.31 Months		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=156									
369195	Extended Safety Follow-up	188	Autoimmune hepatitis	3.71 Months		Y	Y	N/A	Resolved
		188	Drug-induced liver injury	3.71 Months		Y	N	N/A	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1710, Subject ID=369195, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=156									
369195	Extended Safety Follow-up	188	Pneumonitis	3.71 Months		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=1711, Subject ID=368852, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=29									
368852	Safety Follow-up	41	Renal failure acute	Continuing		Y	Y	N/A	Not Resolved
	Extended Safety Follow-up	70	Hyponatraemia	Continuing		Y	N	N/A	Not Resolved
Trial Number=3475-006, Site Number=1807, Subject ID=369310, Gender=F, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=252									
369310	Treatment Cycle 9	139	Squamous cell carcinoma	1.84 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1810, Subject ID=366537, Gender=M, Race=Asian, Age=79 Years, Rel Day of Study Medication Discontinuance†=17									
366537	Safety Follow-up	29	Dehydration	3 Days		Y	N	Interrupted	Resolved

Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1819, Subject ID=368835, Gender=M, Race=White, Age=36 Years, Rel Day of Study Medication Discontinuance†=30									
368835	Safety Follow-up	43	Small intestinal obstruction	3 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1820, Subject ID=362887, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=									
362887	Treatment Cycle 20	272	Basal cell carcinoma	23 Hours		Y	N	None	Resolved
		272	Basal cell carcinoma	23 Hours		Y	N	None	Sequelae
Trial Number=3475-006, Site Number=1820, Subject ID=363942, Gender=M, Race=White, Age=19 Years, Rel Day of Study Medication Discontinuance†=71									
363942	Treatment Cycle 2	15	Pleural effusion	4.24 Months		Y	N	None	Resolved
		15	Pneumonia	Continuing		Y	N	None	Not Resolved
		23	Sepsis	5 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1823, Subject ID=360915, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=146									
360915	Treatment Cycle 6	70	Brain oedema	1.38 Months		Y	N	None	Resolved
		70	Radiation necrosis	1.38 Months		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q2W									
Trial Number=3475-006, Site Number=1823, Subject ID=360915, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=146									
360915	Treatment Cycle 6	126	Pulmonary thrombosis	3 Days		Y	N	Interrupted	Resolved
	Safety Follow-up	162	Partial seizures	1.14 Weeks		Y	N	Discontinued	Resolved
		173	Haematoma	3.43 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1824, Subject ID=360306, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=183									
360306	Treatment Cycle 2	24	Sinusitis	Continuing		Y	Y	None	Not Resolved
	Safety Follow-up	191	Autoimmune hepatitis	1.77 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1825, Subject ID=368965, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†–									
368965	Treatment Cycle 7	94	Atrial fibrillation	3.14 Weeks		Y	N	Interrupted	Resolved
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0001, Subject ID=364591, Gender=M, Race=White, Age=26 Years, Rel Day of Study Medication Discontinuance†=104									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0001, Subject ID=364591, Gender=M, Race=White, Age=26 Years, Rel Day of Study Medication Discontinuance†=104									
364591	Treatment Cycle 4	81	Haemoptysis	5 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0001, Subject ID=368720, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=254									
368720	Treatment Cycle 10 Safety Follow-up	192 262	Confusional state Haemorrhage intracranial	Continuing 3.86 Weeks		Y Y	Y N	Interrupted Discontinued	Not Resolved Resolved
Trial Number=3475-006, Site Number=0002, Subject ID=361272, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†–									
361272	Treatment Cycle 9	183	Pancreatitis	4 Days		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0002, Subject ID=366309, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=1									
366309	Safety Follow-up	5	Cardiac failure congestive	23 Hours		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=0003, Subject ID=364744, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=106									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0003, Subject ID=364744, Gender=M, Race=White, Age=81 Years, Rel Day of Study Medication Discontinuance†=106									
364744	Extended Safety Follow-up	187	Pneumonitis	2.43 Weeks		Y	Y	N/A	Resolved
Trial Number=3475-006, Site Number=0005, Subject ID=363154, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=76									
363154	Treatment Cycle 1	13	Pleural effusion	2.43 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0007, Subject ID=367327, Gender=M, Race=White, Age=56 Years, Rel Day of Study Medication Discontinuance†=29									
367327	Treatment Cycle 1	3	Gastritis	1.81 Months		Y	N	Interrupted	Resolved
		17	Back pain	3.84 Months		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0102, Subject ID=360505, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=65									
360505	Safety Follow-up	71	Rib fracture	1.31 Months		Y	N	None	Sequelae
Trial Number=3475-006, Site Number=0102, Subject ID=364417, Gender=F, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=1									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0102, Subject ID=364417, Gender=F, Race=White, Age=47 Years, Rel Day of Study Medication Discontinuance†=1									
364417	Safety Follow-up	4	Intracranial tumour haemorrhage	1.58 Months		Y	N	Discontinued	Sequelae
Trial Number=3475-006, Site Number=0103, Subject ID=361289, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=63									
361289	Safety Follow-up	78	Pain in extremity	1.29 Weeks		Y	N	None	Resolved
		87	Cardiac failure	1.29 Weeks		Y	N	None	Resolved
	Extended Safety Follow-up	101	Pneumonia	2.71 Weeks		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=0309, Subject ID=366971, Gender=M, Race=White, Age=79 Years, Rel Day of Study Medication Discontinuance†=1									
366971	Safety Follow-up	29	Hepatitis	1.08 Months		Y	Y	Discontinued	Resolved
		29	Pneumonitis	3.88 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0501, Subject ID=362675, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=22									
362675	Safety Follow-up	23	Soft tissue infection	1.29 Weeks		Y	N	Discontinued	Fatal

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0601, Subject ID=360385, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=57									
360385	Safety Follow-up	76	Abdominal pain	2.43 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0601, Subject ID=362914, Gender=M, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=									
362914	Treatment Cycle 2	22	Malignant melanoma	2 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0601, Subject ID=364921, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=23									
364921	Treatment Cycle 1	16	Gastrointestinal haemorrhage	5 Days		Y	N	None	Resolved
		19	Anaemia	Continuing		Y	N	None	Resolving
Trial Number=3475-006, Site Number=0601, Subject ID=364963, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=85									
364963	Safety Follow-up	102	Erysipelas	1.14 Weeks		Y	N	N/A	Resolved
	Extended Safety Follow-up	133	Pathological fracture	2.14 Weeks		Y	N	N/A	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0602, Subject ID=361473, Gender=M, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=67									
361473	Treatment Cycle 4	67	Anaphylactoid reaction	3 Days		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360080, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=274									
360080	Treatment Cycle 3	43	Renal failure acute	1.77 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360314, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=244									
360314	Treatment Cycle 3	63	Pyelonephritis	6 Days		Y	N	None	Resolved
	Safety Follow-up	254	Depression	2.73 Months		Y	N	Discontinued	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=360489, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=54									
360489	Treatment Cycle 1	19	Urinary tract infection	2.43 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 2	48	Anaemia	3 Days		Y	N	None	Resolved
	Safety Follow-up	74	Renal failure	Continuing		Y	N	None	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0605, Subject ID=361293, Gender=F, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=191									
361293	Safety Follow-up	212	Thrombocytopenia	6 Days		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=362662, Gender=F, Race=White, Age=38 Years, Rel Day of Study Medication Discontinuance†=232									
362662	Safety Follow-up	233	Oesophagitis	Continuing		Y	Y	Discontinued	Resolving
		253	Metabolic disorder	5 Days		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=363218, Gender=M, Race=White, Age=75 Years, Rel Day of Study Medication Discontinuance†=190									
363218	Safety Follow-up	191	Hydrocephalus	1.91 Months		Y	N	Interrupted	Resolved
		215	Renal failure	Continuing		Y	Y	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=0605, Subject ID=366256, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=21									
366256	Treatment Cycle 1	6	Cough	4.47 Months		Y	Y	Discontinued	Resolved
	Treatment Cycle 2	21	Thrombocytopenia	Continuing		Y	Y	Discontinued	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0605, Subject ID=369338, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†–									
369338	Treatment Cycle 1	8	Haemoptysis	4 Days		Y	N	None	Resolved
	Treatment Cycle 8	149	Gastritis	1.94 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=364561, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=20									
364561	Treatment Cycle 1	17	Autoimmune hepatitis	3.12 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=364995, Gender=M, Race=White, Age=60 Years, Rel Day of Study Medication Discontinuance†=64									
364995	Extended Safety Follow-up	132	Femur fracture	2 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0611, Subject ID=365059, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=99									
365059	Treatment Cycle 2	22	Hepatitis	1.18 Months		Y	Y	Interrupted	Resolved
		25	Atrial fibrillation	1.05 Months		Y	N	None	Resolved
	Safety Follow-up	108	Lung infection	2.14 Weeks		Y	N	Discontinued	Fatal

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0611, Subject ID=365059, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=99									
365059	Safety Follow-up	108	Pulmonary embolism	Continuing		Y	N	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=361538, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=85									
361538	Treatment Cycle 2	30	Pulmonary embolism	1 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=365642, Gender=M, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=85									
365642	Treatment Cycle 2	43 45	Acute coronary syndrome Pulmonary embolism	3.14 Weeks 2.86 Weeks		Y Y	N N	None Interrupted	Resolved Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=365859, Gender=M, Race=White, Age=32 Years, Rel Day of Study Medication Discontinuance†=316									
365859	Treatment Cycle 4	77	Convulsion	2 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0612, Subject ID=366789, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=211									
366789	Treatment Cycle 1	7	Cerebrovascular accident	6.74 Months		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0612, Subject ID=366789, Gender=M, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=211									
366789	Treatment Cycle 7	146	Orthostatic hypotension	3 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0701, Subject ID=360019, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=64									
360019	Treatment Cycle 3	57	Colitis	3.94 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=0706, Subject ID=363477, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=253									
363477	Treatment Cycle 7	129	Radiation necrosis	2.86 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=0706, Subject ID=367820, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=1									
367820	Safety Follow-up	8	Cardiac failure	4.14 Weeks		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=0706, Subject ID=369387, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=128									
369387	Safety Follow-up	136	Hyponatraemia	4.29 Weeks		Y	N	Interrupted	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=0902, Subject ID=361025, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=–									
361025	Treatment Cycle 7	156	Tubulointerstitial nephritis	1.08 Months		Y	Y	Interrupted	Resolved
Trial Number=3475-006, Site Number=0902, Subject ID=366242, Gender=F, Race=White, Age=41 Years, Rel Day of Study Medication Discontinuance†=85									
366242	Treatment Cycle 2	45	Pathological fracture	1.29 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1201, Subject ID=364788, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=41									
364788	Treatment Cycle 1	10	Cellulitis	1.57 Weeks		Y	N	None	Resolved
	Treatment Cycle 2	36	Malaise	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1400, Subject ID=366877, Gender=F, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=1									
366877	Safety Follow-up	15	Metastases to central nervous system	Continuing		Y	N	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1401, Subject ID=362977, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=259									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1401, Subject ID=362977, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=259									
362977	Treatment Cycle 2	42	Angina unstable	4 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1402, Subject ID=368856, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=85									
368856	Treatment Cycle 3	54	Colitis	6.57 Months		Y	Y	None	Resolved
		54	Diarrhoea	1.68 Months		Y	Y	None	Resolved
	Treatment Cycle 4	68	Hypokalaemia	2.43 Weeks		Y	Y	None	Resolved
		68	Ileus	1.29 Weeks		Y	Y	N/A	Resolved
	Extended Safety Follow-up	132	Vomiting	6 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1500, Subject ID=363996, Gender=M, Race=White, Age=42 Years, Rel Day of Study Medication Discontinuance†=22									
363996	Safety Follow-up	37	Colitis	1.64 Months		Y	Y	Discontinued	Resolved
	Extended Safety Follow-up	87	Hepatic function abnormal	Continuing		Y	Y	None	Resolving

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1500, Subject ID=366146, Gender=M, Race=White, Age=44 Years, Rel Day of Study Medication Discontinuance†=									
366146	Treatment Cycle 10	208	Papillary thyroid cancer	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=365987, Gender=F, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=44									
365987	Treatment Cycle 2	40	Asthenia	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1502, Subject ID=367219, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=21									
367219	Safety Follow-up	36	Respiratory tract infection	5 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1504, Subject ID=365695, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
365695	Treatment Cycle 8	170	Renal failure	6 Days		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1506, Subject ID=364200, Gender=M, Race=White, Age=68 Years, Rel Day of Study Medication Discontinuance†=21									
364200	Treatment Cycle 1	7	Dyspnoea	Continuing		Y	N	Discontinued	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1600, Subject ID=364068, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=135									
364068	Treatment Cycle 2	48	Pulmonary embolism	1.51 Months		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1601, Subject ID=364335, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=45									
364335	Treatment Cycle 1 Treatment Cycle 2	5 41	Convulsion Colitis	3 Days 1.41 Months		Y Y	N Y	N/A Discontinued	Resolved Resolved
Trial Number=3475-006, Site Number=1703, Subject ID=362670, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†–									
362670	Treatment Cycle 10	219	Hypophysitis	2.04 Months		Y	Y	Interrupted	Sequelae
Trial Number=3475-006, Site Number=1703, Subject ID=368103, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
368103	Treatment Cycle 6	116	Chronic obstructive pulmonary disease	6 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1707, Subject ID=364017, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧

006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1707, Subject ID=364017, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†–									
364017	Treatment Cycle 3	52	Hyponatraemia	1.29 Weeks		Y	Y	Interrupted	Resolved
		66	Sepsis	2.14 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1707, Subject ID=364658, Gender=M, Race=White, Age=58 Years, Rel Day of Study Medication Discontinuance†=1									
364658	Safety Follow-up	22	Drug-induced liver injury	3.71 Weeks		Y	Y	Discontinued	Resolved
		22	Drug-induced liver injury	4.29 Weeks		Y	Y	Interrupted	Resolved
		28	Guillain-Barre syndrome	3.15 Months		Y	Y	Discontinued	Sequelae
Trial Number=3475-006, Site Number=1707, Subject ID=368329, Gender=F, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=64									
368329	Safety Follow-up	71	Anaemia	1.43 Weeks		Y	N	Interrupted	Resolved
Trial Number=3475-006, Site Number=1708, Subject ID=362362, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=85									
362362	Safety Follow-up	111	Diarrhoea	1.84 Months		Y	N	N/A	Resolved

Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1711, Subject ID=368193, Gender=F, Race=Asian, Age=30 Years, Rel Day of Study Medication Discontinuance†=43									
368193	Safety Follow-up	67	Rash	2 Days		Y	N	N/A	Resolved
		72	Aspartate aminotransferase increased	1.14 Weeks		Y	N	N/A	Resolved
		72	Sepsis	6 Days		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1804, Subject ID=367122, Gender=F, Race=White, Age=89 Years, Rel Day of Study Medication Discontinuance†=190									
367122	Treatment Cycle 8	167	Papillary thyroid cancer	Continuing		Y	N	None	Not Resolved
Trial Number=3475-006, Site Number=1807, Subject ID=365454, Gender=F, Race=White, Age=59 Years, Rel Day of Study Medication Discontinuance†=141									
365454	Treatment Cycle 3	49	Cardiac failure congestive	3 Weeks		Y	N	Interrupted	Resolved
	Treatment Cycle 4	80	Cardiac failure congestive	2 Days		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1809, Subject ID=361785, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†–									
361785	Treatment Cycle 4	73	Colitis	6 Days		Y	N	None	Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1810, Subject ID=366382, Gender=F, Race=White, Age=71 Years, Rel Day of Study Medication Discontinuance†=43									
366382	Safety Follow-up	64	Failure to thrive	3 Days		Y	N	N/A	Sequelae
Trial Number=3475-006, Site Number=1812, Subject ID=362552, Gender=M, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=22									
362552	Treatment Cycle 1	21	Anaemia	Continuing		Y	N	None	Not Resolved
	Safety Follow-up	43	Completed suicide	1 Seconds		Y	N	Discontinued	Fatal
Trial Number=3475-006, Site Number=1814, Subject ID=367816, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†–									
367816	Treatment Cycle 7	137	Basal cell carcinoma	2.14 Weeks		Y	N	None	Resolved
	Treatment Cycle 8	162	Papilloma	23 Hours		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1815, Subject ID=360878, Gender=M, Race=White, Age=78 Years, Rel Day of Study Medication Discontinuance†=63									
360878	Treatment Cycle 3	46	Colitis	6.34 Months		Y	Y	Discontinued	Resolved
Trial Number=3475-006, Site Number=1819, Subject ID=363551, Gender=F, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=22									

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1819, Subject ID=363551, Gender=F, Race=White, Age=80 Years, Rel Day of Study Medication Discontinuance†=22									
363551	Safety Follow-up	32	Pathological fracture	6 Days		Y	N	None	Resolved
	Extended Safety Follow-up	58	Renal failure acute	1.29 Weeks		Y	N	None	Resolved
		60	Venous thrombosis	1 Weeks		Y	N	None	Sequelae
Trial Number=3475-006, Site Number=1820, Subject ID=360662, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=1									
360662	Safety Follow-up	9	Metastases to central nervous system	Continuing		Y	N	Discontinued	Not Resolved
Trial Number=3475-006, Site Number=1820, Subject ID=364741, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=24									
364741	Treatment Cycle 1	17	Cerebral haemorrhage	1.86 Weeks		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1823, Subject ID=362113, Gender=F, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=85									
362113	Safety Follow-up	106	Type 1 diabetes mellitus	Continuing		Y	Y	Discontinued	Not Resolved

C Confidential

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1823, Subject ID=362514, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=63									
362514	Treatment Cycle 3	46	Dyspnoea	1.84 Months		Y	N	None	Resolved
Trial Number=3475-006, Site Number=1900, Subject ID=363703, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=1									
363703	Safety Follow-up	29	Bronchitis	1.84 Months		Y	N	N/A	Resolved
Trial Number=3475-006, Site Number=1900, Subject ID=364375, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=129									

付録 2.7.4-31 最終投与後 90 日までに発現した重篤な有害事象の一覧
006 試験（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Intensity	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-006, Site Number=1900, Subject ID=364375, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=129									
364375	Treatment Cycle 3	55	Fatigue	Continuing		Y	N	None	Not Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

MedDRA preferred terms 'Malignant neoplasm progression' and 'Neoplasm progression' not related to the drug are excluded.

SAEs were followed 90 days after last dose of study treatment.

(Database Cutoff Date: 03SEP2014).

Data Source: [資料5.3.5.1.2: P006V01]

Confidential

付録 2.7.4-32 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
006 試験（MK-3475 併合）（APaT 集団）

	Control		MK-3475 combined	
	n	(%)	n	(%)
Subjects in population	256		555	
with one or more adverse events	46	(18.0)	53	(9.5)
with no adverse events	210	(82.0)	502	(90.5)
Blood and lymphatic system disorders	**0**	**(0.0)**	**2**	**(0.4)**
Anaemia	0	(0.0)	1	(0.2)
Thrombocytopenia	0	(0.0)	1	(0.2)
Endocrine disorders	**5**	**(2.0)**	**5**	**(0.9)**
Adrenal insufficiency	1	(0.4)	2	(0.4)
Hypophysitis	2	(0.8)	1	(0.2)
Hypopituitarism	2	(0.8)	1	(0.2)
Thyroiditis	0	(0.0)	1	(0.2)
Eye disorders	**2**	**(0.8)**	**0**	**(0.0)**
Diplopia	1	(0.4)	0	(0.0)
Uveitis	1	(0.4)	0	(0.0)
Gastrointestinal disorders	**27**	**(10.5)**	**19**	**(3.4)**
Abdominal pain	1	(0.4)	0	(0.0)
Autoimmune pancreatitis	0	(0.0)	1	(0.2)
Colitis	16	(6.3)	9	(1.6)
Diarrhoea	10	(3.9)	9	(1.6)
Enterocolitis	2	(0.8)	0	(0.0)
Ileus	0	(0.0)	1	(0.2)
Large intestine perforation	1	(0.4)	0	(0.0)
Oesophagitis	0	(0.0)	1	(0.2)
General disorders and administration site conditions	**2**	**(0.8)**	**0**	**(0.0)**
Death	1	(0.4)	0	(0.0)
Pyrexia	1	(0.4)	0	(0.0)
Hepatobiliary disorders	**4**	**(1.6)**	**9**	**(1.6)**
Autoimmune hepatitis	1	(0.4)	4	(0.7)

Confidential

付録 2.7.4-32 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
006 試験（MK-3475 併合）（APaT 集団）（続き）

	Control		MK-3475 combined	
	n	(%)	n	(%)
Hepatobiliary disorders	**4**	**(1.6)**	**9**	**(1.6)**
Drug-induced liver injury	0	(0.0)	1	(0.2)
Hepatic function abnormal	0	(0.0)	1	(0.2)
Hepatitis	0	(0.0)	3	(0.5)
Hepatocellular injury	2	(0.8)	0	(0.0)
Hepatotoxicity	1	(0.4)	0	(0.0)
Immune system disorders	**0**	**(0.0)**	**2**	**(0.4)**
Anaphylactoid reaction	0	(0.0)	1	(0.2)
Drug hypersensitivity	0	(0.0)	1	(0.2)
Infections and infestations	**2**	**(0.8)**	**5**	**(0.9)**
Bacterial sepsis	0	(0.0)	1	(0.2)
Colonic abscess	1	(0.4)	0	(0.0)
Encephalitis	0	(0.0)	1	(0.2)
Liver abscess	0	(0.0)	1	(0.2)
Meningitis	0	(0.0)	1	(0.2)
Myelitis	1	(0.4)	0	(0.0)
Sinusitis	0	(0.0)	1	(0.2)
Investigations	**2**	**(0.8)**	**2**	**(0.4)**
Alanine aminotransferase increased	2	(0.8)	0	(0.0)
Aspartate aminotransferase increased	1	(0.4)	0	(0.0)
Blood corticotrophin decreased	0	(0.0)	1	(0.2)
Liver function test abnormal	0	(0.0)	1	(0.2)
Metabolism and nutrition disorders	**1**	**(0.4)**	**6**	**(1.1)**
Hypoalbuminaemia	0	(0.0)	1	(0.2)
Hypokalaemia	0	(0.0)	2	(0.4)
Hyponatraemia	1	(0.4)	1	(0.2)
Metabolic disorder	0	(0.0)	1	(0.2)
Type 1 diabetes mellitus	0	(0.0)	1	(0.2)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**1**	**(0.2)**

C Confidential

付録 2.7.4-32 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
006 試験（MK-3475 併合）（APaT 集団）（続き）

	Control		MK-3475 combined	
	n	(%)	n	(%)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**1**	**(0.2)**
Myalgia	0	(0.0)	1	(0.2)
Nervous system disorders	**2**	**(0.8)**	**4**	**(0.7)**
Encephalopathy	1	(0.4)	0	(0.0)
Epilepsy	0	(0.0)	1	(0.2)
Guillain-Barre syndrome	0	(0.0)	1	(0.2)
Haemorrhagic stroke	0	(0.0)	1	(0.2)
Horner's syndrome	1	(0.4)	0	(0.0)
Peripheral motor neuropathy	0	(0.0)	1	(0.2)
Psychiatric disorders	**1**	**(0.4)**	**1**	**(0.2)**
Confusional state	1	(0.4)	1	(0.2)
Renal and urinary disorders	**2**	**(0.8)**	**3**	**(0.5)**
Renal failure	1	(0.4)	1	(0.2)
Renal failure acute	1	(0.4)	1	(0.2)
Tubulointerstitial nephritis	0	(0.0)	1	(0.2)
Respiratory, thoracic and mediastinal disorders	**2**	**(0.8)**	**6**	**(1.1)**
Cough	0	(0.0)	2	(0.4)
Pneumonitis	2	(0.8)	4	(0.7)
Skin and subcutaneous tissue disorders	**1**	**(0.4)**	**1**	**(0.2)**
Lichen planus	0	(0.0)	1	(0.2)
Rash	1	(0.4)	0	(0.0)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
SAEs were followed 90 days after last dose of study treatment
(Database Cutoff Date: 03SEP2014).

Data Source: [資料5.3.5.1.2: P006V01]

Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	340		769		458		1,567	
with one or more adverse events	138	(40.6)	245	(31.9)	142	(31.0)	525	(33.5)
with no adverse events	202	(59.4)	524	(68.1)	316	(69.0)	1,042	(66.5)
Blood and lymphatic system disorders	**10**	**(2.9)**	**11**	**(1.4)**	**13**	**(2.8)**	**34**	**(2.2)**
Anaemia	9	(2.6)	7	(0.9)	7	(1.5)	23	(1.5)
Disseminated intravascular coagulation	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Haemolytic anaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Immune thrombocytopenic purpura	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Iron deficiency anaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Leukocytosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pancytopenia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Splenic infarction	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Thrombocytopenia	1	(0.3)	3	(0.4)	0	(0.0)	4	(0.3)
Cardiac disorders	**9**	**(2.6)**	**19**	**(2.5)**	**7**	**(1.5)**	**35**	**(2.2)**
Acute coronary syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Acute myocardial infarction	0	(0.0)	1	(0.1)	2	(0.4)	3	(0.2)
Angina pectoris	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Angina unstable	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Atrial fibrillation	1	(0.3)	4	(0.5)	2	(0.4)	7	(0.4)
Atrial flutter	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Atrial thrombosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Cardiac arrest	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Cardiac failure	0	(0.0)	3	(0.4)	2	(0.4)	5	(0.3)
Cardiac failure congestive	2	(0.6)	3	(0.4)	1	(0.2)	6	(0.4)
Cardiac ventricular disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Cardiogenic shock	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Coronary artery disease	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Myocardial infarction	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Pericardial effusion	3	(0.9)	1	(0.1)	1	(0.2)	5	(0.3)
Pericarditis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Cardiac disorders	**9**	**(2.6)**	**19**	**(2.5)**	**7**	**(1.5)**	**35**	**(2.2)**
Supraventricular tachycardia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Tachycardia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Congenital, familial and genetic disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**
Aplasia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Ear and labyrinth disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**
Vertigo positional	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Endocrine disorders	**4**	**(1.2)**	**9**	**(1.2)**	**5**	**(1.1)**	**18**	**(1.1)**
Adrenal insufficiency	0	(0.0)	2	(0.3)	2	(0.4)	4	(0.3)
Adrenocortical insufficiency acute	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Hyperparathyroidism	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hyperthyroidism	1	(0.3)	1	(0.1)	1	(0.2)	3	(0.2)
Hypophysitis	3	(0.9)	1	(0.1)	0	(0.0)	4	(0.3)
Hypopituitarism	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Hypothyroidism	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Thyroiditis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Eye disorders	**1**	**(0.3)**	**2**	**(0.3)**	**1**	**(0.2)**	**4**	**(0.3)**
Eye movement disorder	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Glaucoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Iritis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Visual acuity reduced	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Gastrointestinal disorders	**32**	**(9.4)**	**56**	**(7.3)**	**42**	**(9.2)**	**130**	**(8.3)**
Abdominal distension	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Abdominal mass	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Abdominal pain	3	(0.9)	10	(1.3)	3	(0.7)	16	(1.0)
Abdominal pain lower	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Anal fistula	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Ascites	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Autoimmune pancreatitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Colitis	4	(1.2)	12	(1.6)	6	(1.3)	22	(1.4)
Colitis microscopic	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Gastrointestinal disorders	**32**	**(9.4)**	**56**	**(7.3)**	**42**	**(9.2)**	**130**	**(8.3)**
Constipation	3	(0.9)	4	(0.5)	0	(0.0)	7	(0.4)
Diarrhoea	2	(0.6)	6	(0.8)	15	(3.3)	23	(1.5)
Diverticulitis intestinal haemorrhagic	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Diverticulum	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Dysphagia	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Gastric disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Gastric ulcer haemorrhage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Gastritis	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Gastrointestinal disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Gastrointestinal haemorrhage	0	(0.0)	2	(0.3)	3	(0.7)	5	(0.3)
Gastrointestinal pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Gastrointestinal ulcer	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Haematemesis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Ileus	1	(0.3)	4	(0.5)	0	(0.0)	5	(0.3)
Intestinal obstruction	2	(0.6)	2	(0.3)	3	(0.7)	7	(0.4)
Intestinal perforation	0	(0.0)	0	(0.0)	2	(0.4)	2	(0.1)
Intussusception	1	(0.3)	1	(0.1)	1	(0.2)	3	(0.2)
Large intestinal ulcer	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Malabsorption	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Nausea	3	(0.9)	3	(0.4)	3	(0.7)	9	(0.6)
Obstruction gastric	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Odynophagia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Oesophagitis	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Pancreatitis	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Proctalgia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Retroperitoneal haemorrhage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Small intestinal obstruction	1	(0.3)	1	(0.1)	2	(0.4)	4	(0.3)
Small intestinal perforation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Stomatitis necrotising	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Upper gastrointestinal haemorrhage	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Vomiting	6	(1.8)	5	(0.7)	3	(0.7)	14	(0.9)

Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**21**	**(6.2)**	**31**	**(4.0)**	**18**	**(3.9)**	**70**	**(4.5)**
Asthenia	2	(0.6)	5	(0.7)	1	(0.2)	8	(0.5)
Chest pain	2	(0.6)	0	(0.0)	1	(0.2)	3	(0.2)
Chills	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Death	3	(0.9)	3	(0.4)	3	(0.7)	9	(0.6)
Device dislocation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Drug withdrawal syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Fatigue	1	(0.3)	3	(0.4)	1	(0.2)	5	(0.3)
Gait disturbance	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
General physical health deterioration	1	(0.3)	6	(0.8)	2	(0.4)	9	(0.6)
Generalised oedema	4	(1.2)	0	(0.0)	1	(0.2)	5	(0.3)
Impaired healing	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Inflammation	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Influenza like illness	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Infusion site extravasation	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Malaise	2	(0.6)	1	(0.1)	1	(0.2)	4	(0.3)
Non-cardiac chest pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Oedema	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Oedema peripheral	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pain	1	(0.3)	5	(0.7)	0	(0.0)	6	(0.4)
Pyrexia	6	(1.8)	7	(0.9)	5	(1.1)	18	(1.1)
Hepatobiliary disorders	**5**	**(1.5)**	**9**	**(1.2)**	**7**	**(1.5)**	**21**	**(1.3)**
Autoimmune hepatitis	1	(0.3)	2	(0.3)	3	(0.7)	6	(0.4)
Bile duct obstruction	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Bile duct stone	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Cholecystitis	2	(0.6)	1	(0.1)	1	(0.2)	4	(0.3)
Drug-induced liver injury	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Hepatic failure	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Hepatic function abnormal	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hepatitis	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Hyperbilirubinaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Immune system disorders	**0**	**(0.0)**	**3**	**(0.4)**	**1**	**(0.2)**	**4**	**(0.3)**

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Immune system disorders	**0**	**(0.0)**	**3**	**(0.4)**	**1**	**(0.2)**	**4**	**(0.3)**
Anaphylactic reaction	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Anaphylactoid reaction	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Drug hypersensitivity	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hypersensitivity	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Infections and infestations	**32**	**(9.4)**	**44**	**(5.7)**	**28**	**(6.1)**	**104**	**(6.6)**
Appendicitis perforated	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Bacterial sepsis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Bronchitis	2	(0.6)	2	(0.3)	1	(0.2)	5	(0.3)
Candida infection	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Catheter site infection	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Cellulitis	2	(0.6)	8	(1.0)	3	(0.7)	13	(0.8)
Clostridium difficile colitis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Clostridium difficile infection	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Diverticulitis	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Encephalitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Enterocolitis infectious	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Erysipelas	2	(0.6)	2	(0.3)	0	(0.0)	4	(0.3)
Escherichia bacteraemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Gastroenteritis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Gastroenteritis viral	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Herpes simplex encephalitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Herpes zoster	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Infectious pleural effusion	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Influenza	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Liver abscess	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Localised infection	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Lung infection	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Lyme disease	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Mastitis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Meningitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Pelvic abscess	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pneumonia	8	(2.4)	9	(1.2)	9	(2.0)	26	(1.7)
Pyelonephritis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Infections and infestations	**32**	**(9.4)**	**44**	**(5.7)**	**28**	**(6.1)**	**104**	**(6.6)**
Respiratory tract infection	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Salmonellosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Sepsis	3	(0.9)	3	(0.4)	4	(0.9)	10	(0.6)
Septic shock	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Sinusitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Skin infection	2	(0.6)	1	(0.1)	0	(0.0)	3	(0.2)
Soft tissue infection	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Tuberculosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Upper respiratory tract infection	1	(0.3)	0	(0.0)	1	(0.2)	2	(0.1)
Urinary tract infection	2	(0.6)	6	(0.8)	4	(0.9)	12	(0.8)
Viral infection	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Wound infection	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Injury, poisoning and procedural complications	**4**	**(1.2)**	**12**	**(1.6)**	**4**	**(0.9)**	**20**	**(1.3)**
Facial bones fracture	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Fall	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Femoral neck fracture	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Femur fracture	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hip fracture	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Humerus fracture	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Joint injury	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Lower limb fracture	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Procedural pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Radiation injury	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Radiation necrosis	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Rib fracture	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Spinal fracture	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Wound decomposition	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Wound haemorrhage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Investigations	**0**	**(0.0)**	**5**	**(0.7)**	**3**	**(0.7)**	**8**	**(0.5)**
Alanine aminotransferase increased	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)

Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Investigations	**0**	**(0.0)**	**5**	**(0.7)**	**3**	**(0.7)**	**8**	**(0.5)**
Aspartate aminotransferase increased	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Bilirubin conjugated increased	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Blood corticotrophin decreased	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Electrocardiogram change	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Liver function test abnormal	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Medical observation	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Metabolism and nutrition disorders	**17**	**(5.0)**	**23**	**(3.0)**	**17**	**(3.7)**	**57**	**(3.6)**
Cachexia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Decreased appetite	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Dehydration	6	(1.8)	3	(0.4)	4	(0.9)	13	(0.8)
Diabetes mellitus	2	(0.6)	0	(0.0)	1	(0.2)	3	(0.2)
Diabetic ketoacidosis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Electrolyte imbalance	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Failure to thrive	1	(0.3)	2	(0.3)	2	(0.4)	5	(0.3)
Gout	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hypercalcaemia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Hyperglycaemia	2	(0.6)	1	(0.1)	0	(0.0)	3	(0.2)
Hyperkalaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hyperuricaemia	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Hypoalbuminaemia	0	(0.0)	0	(0.0)	2	(0.4)	2	(0.1)
Hypoglycaemia	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Hypokalaemia	0	(0.0)	2	(0.3)	2	(0.4)	4	(0.3)
Hyponatraemia	2	(0.6)	8	(1.0)	5	(1.1)	15	(1.0)
Insulin resistant diabetes	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Malnutrition	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Metabolic acidosis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Metabolic disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Type 1 diabetes mellitus	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Musculoskeletal and connective tissue disorders	**4**	**(1.2)**	**22**	**(2.9)**	**11**	**(2.4)**	**37**	**(2.4)**
Arthralgia	0	(0.0)	4	(0.5)	0	(0.0)	4	(0.3)
Back pain	1	(0.3)	2	(0.3)	2	(0.4)	5	(0.3)
Costochondritis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Flank pain	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Groin pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Muscular weakness	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Musculoskeletal chest pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Musculoskeletal pain	2	(0.6)	1	(0.1)	1	(0.2)	4	(0.3)
Myalgia	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Myopathy	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Myositis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Neck pain	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Osteolysis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pain in extremity	2	(0.6)	1	(0.1)	1	(0.2)	4	(0.3)
Pathological fracture	0	(0.0)	4	(0.5)	2	(0.4)	6	(0.4)
Polyarthritis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Rhabdomyolysis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Spinal pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Spondylolisthesis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Synovial cyst	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**18**	**(5.3)**	**19**	**(2.5)**	**21**	**(4.6)**	**58**	**(3.7)**
Adenocarcinoma	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Adenocarcinoma gastric	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Basal cell carcinoma	4	(1.2)	3	(0.4)	3	(0.7)	10	(0.6)
Basosquamous carcinoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Cancer pain	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Desmoplastic melanoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Gastrointestinal carcinoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Intracranial tumour haemorrhage	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**18**	**(5.3)**	**19**	**(2.5)**	**21**	**(4.6)**	**58**	**(3.7)**
Lymphangiosis carcinomatosa	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Malignant melanoma	2	(0.6)	1	(0.1)	2	(0.4)	5	(0.3)
Metastases to central nervous system	3	(0.9)	2	(0.3)	1	(0.2)	6	(0.4)
Metastases to lymph nodes	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Metastases to meninges	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Metastatic malignant melanoma	0	(0.0)	0	(0.0)	2	(0.4)	2	(0.1)
Metastatic pain	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Oncologic complication	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Papillary thyroid cancer	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Papilloma	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Squamous cell carcinoma	1	(0.3)	5	(0.7)	6	(1.3)	12	(0.8)
Tumour haemorrhage	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Tumour pain	4	(1.2)	1	(0.1)	0	(0.0)	5	(0.3)
Nervous system disorders	**18**	**(5.3)**	**31**	**(4.0)**	**15**	**(3.3)**	**64**	**(4.1)**
Brain oedema	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Cerebral haemorrhage	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Cerebrovascular accident	2	(0.6)	2	(0.3)	0	(0.0)	4	(0.3)
Convulsion	1	(0.3)	5	(0.7)	2	(0.4)	8	(0.5)
Depressed level of consciousness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Dizziness	2	(0.6)	4	(0.5)	0	(0.0)	6	(0.4)
Dysarthria	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Encephalopathy	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Epilepsy	1	(0.3)	1	(0.1)	1	(0.2)	3	(0.2)
Guillain-Barre syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Haemorrhage intracranial	2	(0.6)	1	(0.1)	0	(0.0)	3	(0.2)
Haemorrhagic stroke	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Headache	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Nervous system disorders	**18**	**(5.3)**	**31**	**(4.0)**	**15**	**(3.3)**	**64**	**(4.1)**
Hemiparesis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hydrocephalus	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Ischaemic stroke	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Lethargy	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Lumbar radiculopathy	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Meningitis noninfective	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Migraine	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Myasthenic syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Neuralgia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Neuropathy peripheral	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Paraesthesia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Partial seizures	3	(0.9)	0	(0.0)	1	(0.2)	4	(0.3)
Peripheral motor neuropathy	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Peripheral sensory neuropathy	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Sciatica	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Spinal cord compression	2	(0.6)	2	(0.3)	4	(0.9)	8	(0.5)
Syncope	2	(0.6)	1	(0.1)	2	(0.4)	5	(0.3)
Psychiatric disorders	**7**	**(2.1)**	**8**	**(1.0)**	**0**	**(0.0)**	**15**	**(1.0)**
Completed suicide	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Confusional state	4	(1.2)	6	(0.8)	0	(0.0)	10	(0.6)
Delirium	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Depression	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Mental status changes	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Renal and urinary disorders	**4**	**(1.2)**	**15**	**(2.0)**	**14**	**(3.1)**	**33**	**(2.1)**
Hydronephrosis	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Nephrolithiasis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Postrenal failure	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Renal failure	0	(0.0)	7	(0.9)	4	(0.9)	11	(0.7)
Renal failure acute	1	(0.3)	6	(0.8)	5	(1.1)	12	(0.8)
Renal failure chronic	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Renal infarct	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Tubulointerstitial nephritis	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Urinary incontinence	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Renal and urinary disorders	**4**	**(1.2)**	**15**	**(2.0)**	**14**	**(3.1)**	**33**	**(2.1)**
Urinary retention	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Reproductive system and breast disorders	**1**	**(0.3)**	**2**	**(0.3)**	**0**	**(0.0)**	**3**	**(0.2)**
Metrorrhagia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pelvic pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Prostatitis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**22**	**(6.5)**	**40**	**(5.2)**	**22**	**(4.8)**	**84**	**(5.4)**
Acute respiratory failure	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Atelectasis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Bronchial obstruction	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Bronchospasm	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Chronic obstructive pulmonary disease	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Cough	1	(0.3)	1	(0.1)	2	(0.4)	4	(0.3)
Dyspnoea	8	(2.4)	13	(1.7)	2	(0.4)	23	(1.5)
Dyspnoea exertional	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Haemoptysis	1	(0.3)	3	(0.4)	1	(0.2)	5	(0.3)
Haemothorax	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Hiccups	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hypoxia	1	(0.3)	2	(0.3)	1	(0.2)	4	(0.3)
Interstitial lung disease	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Laryngeal inflammation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Lung consolidation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Pleural effusion	5	(1.5)	6	(0.8)	3	(0.7)	14	(0.9)
Pleuritic pain	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonia aspiration	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pneumonitis	1	(0.3)	7	(0.9)	4	(0.9)	12	(0.8)
Pneumothorax	0	(0.0)	0	(0.0)	2	(0.4)	2	(0.1)
Pulmonary embolism	2	(0.6)	8	(1.0)	3	(0.7)	13	(0.8)
Pulmonary haemorrhage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pulmonary thrombosis	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Respiratory failure	0	(0.0)	0	(0.0)	2	(0.4)	2	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**5**	**(1.5)**	**4**	**(0.5)**	**2**	**(0.4)**	**11**	**(0.7)**
Erythema multiforme	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Haemorrhage subcutaneous	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Lichen planus	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Rash	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Rash generalised	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Rash maculo-papular	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Skin mass	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Stevens-Johnson syndrome	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Surgical and medical procedures	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**
Skin neoplasm excision	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Vascular disorders	**6**	**(1.8)**	**11**	**(1.4)**	**10**	**(2.2)**	**27**	**(1.7)**
Aortic stenosis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Deep vein thrombosis	1	(0.3)	1	(0.1)	2	(0.4)	4	(0.3)
Embolism	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Haematoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Haemorrhage	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Haemorrhagic infarction	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Hypotension	1	(0.3)	0	(0.0)	3	(0.7)	4	(0.3)
Intra-abdominal haematoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Orthostatic hypotension	0	(0.0)	3	(0.4)	0	(0.0)	3	(0.2)
Peripheral ischaemia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Phlebitis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Poor venous access	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Superior vena cava occlusion	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Superior vena cava syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Vein disorder	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Vena cava thrombosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)

C Confidential

付録 2.7.4-33 最終投与後 90 日までに発現した重篤な有害事象
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Vascular disorders	**6**	**(1.8)**	**11**	**(1.4)**	**10**	**(2.2)**	**27**	**(1.7)**
Venous thrombosis	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.

Include all treated subjects in PN001 Part B1, B2, B3, D and all subjects in PN002 treated with Pembrolizumab in the original phase, and all subjects in PN006 treated with Pembrolizumab

(MK-3475 PN001 Database Cutoff Date: [redacted]

(MK-3475 PN002 Database Cutoff Date: 12MAY2014).

(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

Confidential

付録 2.7.4-34 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in population	340		769		458		1,567	
with one or more adverse events	29	(8.5)	61	(7.9)	56	(12.2)	146	(9.3)
with no adverse events	311	(91.5)	708	(92.1)	402	(87.8)	1,421	(90.7)
Blood and lymphatic system disorders	**1**	**(0.3)**	**2**	**(0.3)**	**4**	**(0.9)**	**7**	**(0.4)**
Anaemia	1	(0.3)	0	(0.0)	1	(0.2)	2	(0.1)
Haemolytic anaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Immune thrombocytopenic purpura	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Pancytopenia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Thrombocytopenia	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Cardiac disorders	**2**	**(0.6)**	**0**	**(0.0)**	**0**	**(0.0)**	**2**	**(0.1)**
Pericardial effusion	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Pericarditis	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Endocrine disorders	**3**	**(0.9)**	**7**	**(0.9)**	**5**	**(1.1)**	**15**	**(1.0)**
Adrenal insufficiency	0	(0.0)	2	(0.3)	2	(0.4)	4	(0.3)
Hyperthyroidism	1	(0.3)	1	(0.1)	1	(0.2)	3	(0.2)
Hypophysitis	3	(0.9)	1	(0.1)	0	(0.0)	4	(0.3)
Hypopituitarism	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Hypothyroidism	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Thyroiditis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Eye disorders	**0**	**(0.0)**	**1**	**(0.1)**	**0**	**(0.0)**	**1**	**(0.1)**
Iritis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Gastrointestinal disorders	**9**	**(2.6)**	**15**	**(2.0)**	**22**	**(4.8)**	**46**	**(2.9)**
Abdominal pain	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Autoimmune pancreatitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Colitis	3	(0.9)	9	(1.2)	5	(1.1)	17	(1.1)
Colitis microscopic	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Diarrhoea	1	(0.3)	4	(0.5)	10	(2.2)	15	(1.0)
Dysphagia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Enterocolitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Ileus	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Intestinal obstruction	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

C Confidential

付録 2.7.4-34 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Gastrointestinal disorders	**9**	**(2.6)**	**15**	**(2.0)**	**22**	**(4.8)**	**46**	**(2.9)**
Nausea	1	(0.3)	0	(0.0)	2	(0.4)	3	(0.2)
Oesophagitis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Pancreatitis	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Small intestinal perforation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Upper gastrointestinal haemorrhage	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Vomiting	1	(0.3)	0	(0.0)	2	(0.4)	3	(0.2)
General disorders and administration site conditions	**5**	**(1.5)**	**7**	**(0.9)**	**4**	**(0.9)**	**16**	**(1.0)**
Asthenia	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Chest pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Death	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Fatigue	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
General physical health deterioration	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Generalised oedema	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.1)
Pyrexia	0	(0.0)	4	(0.5)	3	(0.7)	7	(0.4)
Hepatobiliary disorders	**1**	**(0.3)**	**6**	**(0.8)**	**4**	**(0.9)**	**11**	**(0.7)**
Autoimmune hepatitis	1	(0.3)	2	(0.3)	3	(0.7)	6	(0.4)
Drug-induced liver injury	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hepatic function abnormal	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hepatitis	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Immune system disorders	**0**	**(0.0)**	**2**	**(0.3)**	**1**	**(0.2)**	**3**	**(0.2)**
Anaphylactic reaction	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Anaphylactoid reaction	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Drug hypersensitivity	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Infections and infestations	**0**	**(0.0)**	**3**	**(0.4)**	**6**	**(1.3)**	**9**	**(0.6)**
Bacterial sepsis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Diverticulitis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Encephalitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

C Confidential

付録 2.7.4-34 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Infections and infestations	**0**	**(0.0)**	**3**	**(0.4)**	**6**	**(1.3)**	**9**	**(0.6)**
Erysipelas	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Liver abscess	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Meningitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Sinusitis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Tuberculosis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Investigations	**0**	**(0.0)**	**1**	**(0.1)**	**2**	**(0.4)**	**3**	**(0.2)**
Alanine aminotransferase increased	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Aspartate aminotransferase increased	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Blood corticotrophin decreased	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Liver function test abnormal	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Metabolism and nutrition disorders	**2**	**(0.6)**	**7**	**(0.9)**	**5**	**(1.1)**	**14**	**(0.9)**
Dehydration	1	(0.3)	0	(0.0)	2	(0.4)	3	(0.2)
Failure to thrive	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hyperglycaemia	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Hypoalbuminaemia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Hypokalaemia	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Hyponatraemia	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Insulin resistant diabetes	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Metabolic disorder	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Type 1 diabetes mellitus	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**4**	**(0.5)**	**4**	**(0.9)**	**8**	**(0.5)**
Arthralgia	0	(0.0)	2	(0.3)	0	(0.0)	2	(0.1)
Muscular weakness	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Myalgia	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Myopathy	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

C Confidential

付録 2.7.4-34 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**4**	**(0.5)**	**4**	**(0.9)**	**8**	**(0.5)**
Myositis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Polyarthritis	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Rhabdomyolysis	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.2)**	**1**	**(0.1)**
Malignant melanoma	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Nervous system disorders	**2**	**(0.6)**	**6**	**(0.8)**	**4**	**(0.9)**	**12**	**(0.8)**
Brain oedema	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Depressed level of consciousness	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Dysarthria	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Encephalopathy	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Epilepsy	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Guillain-Barre syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Haemorrhagic stroke	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Meningitis noninfective	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Myasthenic syndrome	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Partial seizures	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Peripheral motor neuropathy	0	(0.0)	1	(0.1)	1	(0.2)	2	(0.1)
Peripheral sensory neuropathy	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Psychiatric disorders	**1**	**(0.3)**	**2**	**(0.3)**	**0**	**(0.0)**	**3**	**(0.2)**
Confusional state	1	(0.3)	2	(0.3)	0	(0.0)	3	(0.2)
Renal and urinary disorders	**1**	**(0.3)**	**4**	**(0.5)**	**4**	**(0.9)**	**9**	**(0.6)**
Renal failure	0	(0.0)	2	(0.3)	1	(0.2)	3	(0.2)
Renal failure acute	0	(0.0)	1	(0.1)	2	(0.4)	3	(0.2)
Tubulointerstitial nephritis	1	(0.3)	1	(0.1)	0	(0.0)	2	(0.1)
Urinary incontinence	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)

C Confidential

付録 2.7.4-34 最終投与後 90 日までに発現した重篤な副作用
（いずれかの投与群で発現割合 0%超）
001 試験+002 試験+006 試験（APaT 集団）（続き）

	MK-3475 2 mg/kg Q3W		MK-3475 10 mg/kg Q3W		MK-3475 10 mg/kg Q2W		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Reproductive system and breast disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**
Pelvic pain	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**4**	**(1.2)**	**10**	**(1.3)**	**8**	**(1.7)**	**22**	**(1.4)**
Cough	0	(0.0)	1	(0.1)	2	(0.4)	3	(0.2)
Dyspnoea	2	(0.6)	1	(0.1)	1	(0.2)	4	(0.3)
Interstitial lung disease	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Laryngeal inflammation	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Pleuritic pain	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonitis	1	(0.3)	7	(0.9)	4	(0.9)	12	(0.8)
Skin and subcutaneous tissue disorders	**2**	**(0.6)**	**1**	**(0.1)**	**1**	**(0.2)**	**4**	**(0.3)**
Erythema multiforme	0	(0.0)	1	(0.1)	0	(0.0)	1	(0.1)
Lichen planus	0	(0.0)	0	(0.0)	1	(0.2)	1	(0.1)
Rash maculo-papular	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Stevens-Johnson syndrome	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)
Vascular disorders	**1**	**(0.3)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(0.1)**
Peripheral ischaemia	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.1)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
Include all treated subjects in PN001 Part B1, B2, B3, D and all subjects in PN002 treated with Pembrolizumab in the original phase, and all subjects in PN006 treated with Pembrolizumab
(MK-3475 PN001 Database Cutoff Date: [redacted]
(MK-3475 PN002 Database Cutoff Date: 12MAY2014).
(MK-3475 PN006 Database Cutoff Date: 03SEP2014).

C Confidential

付録 2.7.4-35 重篤な有害事象の一覧

011 試験（APaT 集団）

Randomization Number	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome	Therapy
MK-3475 10 mg/kg Q2W										
Trial Number=3475-011, Site Number=0002, Patient ID=010013, Gender=M, Race=Asian, Age=53 Years, Rel Day of Study Medication Discontinuance†=29										
010013	Safety Follow-up	42	Alanine aminotransferase increased	62 Days	3	Y	Y	Interrupted	Resolved	13 days since last dose
		42	Aspartate aminotransferase increased	62 Days	3	Y	Y	Interrupted	Resolved	13 days since last dose
	Post-study	103	Cerebral infarction	43 Days	4	Y	N	Discontinued	Sequelae	2 months 13 days since last dose

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the patient relative to the start of study medication.
Action Taken: Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN.
Outcome: Resolved = RECOVERED/RESOLVED, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE.
Y=YES, N=NO.
Related: Investigator-assessed relationship of the adverse event to study medication.
Grades are based on CTCAE Version 4.0.
MedDRA preferred terms 'Malignant neoplasm progression' not related to the drug are excluded.

Data Source: [資料5.3.5.2.2: P011V01]

C Confidential

付録 2.7.4-36 最終投与後 90 日までに発現した重篤な有害事象（発現割合 0%超）
041 試験（APaT 集団）

	Subjects With Advanced Melanoma	
	n	(%)
Subjects in population	42	
with one or more adverse events	15	(35.7)
with no adverse events	27	(64.3)
Blood and lymphatic system disorders	**2**	**(4.8)**
Anaemia	2	(4.8)
Endocrine disorders	**2**	**(4.8)**
Hypophysitis	2	(4.8)
Gastrointestinal disorders	**3**	**(7.1)**
Abdominal pain	1	(2.4)
Colitis	1	(2.4)
Diarrhoea	1	(2.4)
Duodenal ulcer haemorrhage	1	(2.4)
Large intestinal obstruction	1	(2.4)
General disorders and administration site conditions	**1**	**(2.4)**
Death	1	(2.4)
Hepatobiliary disorders	**1**	**(2.4)**
Bile duct obstruction	1	(2.4)
Infections and infestations	**3**	**(7.1)**
Cellulitis	1	(2.4)

Confidential

付録 2.7.4-36 最終投与後 90 日までに発現した重篤な有害事象（発現割合 0%超）
041 試験（APaT 集団）（続き）

	Subjects With Advanced Melanoma	
	n	(%)
Infections and infestations	**3**	**(7.1)**
Lung infection	1	(2.4)
Vestibular neuronitis	1	(2.4)
Metabolism and nutrition disorders	**2**	**(4.8)**
Diabetes mellitus	1	(2.4)
Hyperglycaemia	1	(2.4)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**1**	**(2.4)**
Cancer pain	1	(2.4)
Nervous system disorders	**1**	**(2.4)**
Cerebral haemorrhage	1	(2.4)
Encephalopathy	1	(2.4)
Respiratory, thoracic and mediastinal disorders	**2**	**(4.8)**
Acute respiratory failure	1	(2.4)
Pneumonitis	1	(2.4)
Skin and subcutaneous tissue disorders	**1**	**(2.4)**

C Confidential

付録 2.7.4-36 最終投与後 90 日までに発現した重篤な有害事象（発現割合 0%超）
041 試験（APaT 集団）（続き）

	Subjects With Advanced Melanoma	
	n	(%)
Skin and subcutaneous tissue disorders	**1**	**(2.4)**
Drug eruption	1	(2.4)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.
Adverse event terms are from MedDRA Version 18.0.
(Data Cutoff Date: [redacted]).

Data Source: [資料5.3.5.2.3: P041V01]

Confidential

付録 2.7.4-37 最終投与後 90 日までに発現した重篤な副作用（発現割合 0%超）
041 試験（APaT 集団）

	Subjects With Advanced Melanoma	
	n	(%)
Subjects in population	42	
with one or more adverse events	10	(23.8)
with no adverse events	32	(76.2)
Blood and lymphatic system disorders	**1**	**(2.4)**
Anaemia	1	(2.4)
Endocrine disorders	**2**	**(4.8)**
Hypophysitis	2	(4.8)
Gastrointestinal disorders	**1**	**(2.4)**
Abdominal pain	1	(2.4)
Colitis	1	(2.4)
Diarrhoea	1	(2.4)
General disorders and administration site conditions	**1**	**(2.4)**
Death	1	(2.4)
Hepatobiliary disorders	**1**	**(2.4)**
Bile duct obstruction	1	(2.4)
Infections and infestations	**1**	**(2.4)**
Lung infection	1	(2.4)

Confidential

付録 2.7.4-37 最終投与後 90 日までに発現した重篤な副作用（発現割合 0%超）
041 試験（APaT 集団）（続き）

	Subjects With Advanced Melanoma	
	n	(%)
Metabolism and nutrition disorders	**1**	**(2.4)**
Hyperglycaemia	1	(2.4)
Nervous system disorders	**1**	**(2.4)**
Cerebral haemorrhage	1	(2.4)
Encephalopathy	1	(2.4)
Respiratory, thoracic and mediastinal disorders	**1**	**(2.4)**
Pneumonitis	1	(2.4)
Skin and subcutaneous tissue disorders	**1**	**(2.4)**
Drug eruption	1	(2.4)

Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
MedDRA preferred terms "Neoplasm Progression", "Malignant Neoplasm Progression" and "Disease Progression" not related to the drug are excluded.
Adverse event terms are from MedDRA Version 18.0.
(Data Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.3: P041V01]

Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）

001 試験パート B2+D（APaT 集団）

	Ipi-naïve 2 mg/kg Q3W		Ipi-naïve 10 mg/kg Q3W		Ipi-exposed 2 mg/kg Q3W		Ipi-exposed 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)	n	(%)
Patients in population	51		52		89		84	
with one or more adverse events	13	(25.5)	10	(19.2)	18	(20.2)	18	(21.4)
with no adverse events	38	(74.5)	42	(80.8)	71	(79.8)	66	(78.6)
Blood and lymphatic system disorders	**2**	**(3.9)**	**1**	**(1.9)**	**1**	**(1.1)**	**1**	**(1.2)**
Anaemia	2	(3.9)	1	(1.9)	1	(1.1)	1	(1.2)
Cardiac disorders	**0**	**(0.0)**	**1**	**(1.9)**	**0**	**(0.0)**	**0**	**(0.0)**
Atrial thrombosis	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Endocrine disorders	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.1)**	**1**	**(1.2)**
Adrenal insufficiency	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Hypophysitis	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Eye disorders	**0**	**(0.0)**	**1**	**(1.9)**	**0**	**(0.0)**	**0**	**(0.0)**
Eye irritation	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Gastrointestinal disorders	**3**	**(5.9)**	**2**	**(3.8)**	**2**	**(2.2)**	**4**	**(4.8)**
Abdominal pain	0	(0.0)	0	(0.0)	1	(1.1)	1	(1.2)
Colitis	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Constipation	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Diarrhoea	1	(2.0)	0	(0.0)	1	(1.1)	3	(3.6)
Gastrointestinal haemorrhage	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Nausea	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Small intestinal obstruction	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Vomiting	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
General disorders and administration site conditions	**1**	**(2.0)**	**1**	**(1.9)**	**3**	**(3.4)**	**1**	**(1.2)**
Asthenia	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Chills	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Fatigue	0	(0.0)	1	(1.9)	3	(3.4)	0	(0.0)
Mucosal inflammation	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Pyrexia	1	(2.0)	0	(0.0)	1	(1.1)	0	(0.0)

C Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）

001 試験パート B2+D（APaT 集団）（続き）

	Total	
	n	(%)
Patients in population	276	
with one or more adverse events	59	(21.4)
with no adverse events	217	(78.6)
Blood and lymphatic system disorders	**5**	**(1.8)**
Anaemia	5	(1.8)
Cardiac disorders	**1**	**(0.4)**
Atrial thrombosis	1	(0.4)
Endocrine disorders	**2**	**(0.7)**
Adrenal insufficiency	1	(0.4)
Hypophysitis	1	(0.4)
Eye disorders	**1**	**(0.4)**
Eye irritation	1	(0.4)
Gastrointestinal disorders	**11**	**(4.0)**
Abdominal pain	2	(0.7)
Colitis	1	(0.4)
Constipation	1	(0.4)
Diarrhoea	5	(1.8)
Gastrointestinal haemorrhage	1	(0.4)
Nausea	1	(0.4)
Small intestinal obstruction	1	(0.4)
Vomiting	1	(0.4)
General disorders and administration site conditions	**6**	**(2.2)**
Asthenia	1	(0.4)
Chills	1	(0.4)
Fatigue	4	(1.4)
Mucosal inflammation	1	(0.4)
Pyrexia	2	(0.7)

Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）

001 試験パート B2+D（APaT 集団）（続き）

	Ipi-naïve 2 mg/kg Q3W		Ipi-naïve 10 mg/kg Q3W		Ipi-exposed 2 mg/kg Q3W		Ipi-exposed 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)	n	(%)
Hepatobiliary disorders	**0**	**(0.0)**	**0**	**(0.0)**	**2**	**(2.2)**	**1**	**(1.2)**
Cholecystitis	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Hepatitis	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Hepatomegaly	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Infections and infestations	**3**	**(5.9)**	**4**	**(7.7)**	**1**	**(1.1)**	**2**	**(2.4)**
Catheter site infection	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Cellulitis	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Diverticulitis	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Nasopharyngitis	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Sepsis	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Skin infection	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Tuberculosis	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Upper respiratory tract infection	2	(3.9)	0	(0.0)	0	(0.0)	0	(0.0)
Viral infection	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Injury, poisoning and procedural complications	**0**	**(0.0)**	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.2)**
Infusion related reaction	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Investigations	**3**	**(5.9)**	**0**	**(0.0)**	**2**	**(2.2)**	**3**	**(3.6)**
Alanine aminotransferase increased	1	(2.0)	0	(0.0)	1	(1.1)	1	(1.2)
Aspartate aminotransferase increased	1	(2.0)	0	(0.0)	1	(1.1)	1	(1.2)
Bilirubin conjugated increased	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Blood bilirubin increased	2	(3.9)	0	(0.0)	1	(1.1)	2	(2.4)
Blood cortisol decreased	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Blood testosterone decreased	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)

C Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）
001 試験パート B2+D（APaT 集団）（続き）

	Total	
	n	(%)
Hepatobiliary disorders	**3**	**(1.1)**
Cholecystitis	1	(0.4)
Hepatitis	1	(0.4)
Hepatomegaly	1	(0.4)
Infections and infestations	**10**	**(3.6)**
Catheter site infection	1	(0.4)
Cellulitis	1	(0.4)
Diverticulitis	1	(0.4)
Nasopharyngitis	1	(0.4)
Sepsis	1	(0.4)
Skin infection	1	(0.4)
Tuberculosis	1	(0.4)
Upper respiratory tract infection	2	(0.7)
Viral infection	1	(0.4)
Injury, poisoning and procedural complications	**1**	**(0.4)**
Infusion related reaction	1	(0.4)
Investigations	**8**	**(2.9)**
Alanine aminotransferase increased	3	(1.1)
Aspartate aminotransferase increased	3	(1.1)
Bilirubin conjugated increased	1	(0.4)
Blood bilirubin increased	5	(1.8)
Blood cortisol decreased	1	(0.4)
Blood testosterone decreased	1	(0.4)

Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）

001 試験パート B2+D（APaT 集団）（続き）

	Ipi-naïve 2 mg/kg Q3W		Ipi-naïve 10 mg/kg Q3W		Ipi-exposed 2 mg/kg Q3W		Ipi-exposed 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**2**	**(3.9)**	**1**	**(1.9)**	**1**	**(1.1)**	**2**	**(2.4)**
Dehydration	1	(2.0)	1	(1.9)	0	(0.0)	1	(1.2)
Failure to thrive	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Hyperuricaemia	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Hyponatraemia	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Musculoskeletal and connective tissue disorders	**0**	**(0.0)**	**0**	**(0.0)**	**3**	**(3.4)**	**1**	**(1.2)**
Arthralgia	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Arthritis	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Muscular weakness	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Myalgia	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**0**	**(0.0)**	**0**	**(0.0)**	**1**	**(1.1)**	**1**	**(1.2)**
Metastases to central nervous system	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Tumour haemorrhage	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Nervous system disorders	**1**	**(2.0)**	**1**	**(1.9)**	**1**	**(1.1)**	**1**	**(1.2)**
Cognitive disorder	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Headache	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Ischaemic stroke	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Syncope	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Respiratory, thoracic and mediastinal disorders	**1**	**(2.0)**	**2**	**(3.8)**	**5**	**(5.6)**	**1**	**(1.2)**
Bronchiectasis	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Cough	1	(2.0)	0	(0.0)	1	(1.1)	0	(0.0)
Dyspnoea	0	(0.0)	1	(1.9)	1	(1.1)	0	(0.0)
Haemoptysis	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Pleural effusion	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Pneumonitis	0	(0.0)	0	(0.0)	1	(1.1)	1	(1.2)
Pulmonary embolism	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)

C Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）
001 試験パート B2+D（APaT 集団）（続き）

	Total	
	n	(%)
Metabolism and nutrition disorders	**6**	**(2.2)**
Dehydration	3	(1.1)
Failure to thrive	1	(0.4)
Hyperuricaemia	1	(0.4)
Hyponatraemia	1	(0.4)
Musculoskeletal and connective tissue disorders	**4**	**(1.4)**
Arthralgia	1	(0.4)
Arthritis	1	(0.4)
Muscular weakness	1	(0.4)
Myalgia	1	(0.4)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**2**	**(0.7)**
Metastases to central nervous system	1	(0.4)
Tumour haemorrhage	1	(0.4)
Nervous system disorders	**4**	**(1.4)**
Cognitive disorder	1	(0.4)
Headache	1	(0.4)
Ischaemic stroke	1	(0.4)
Syncope	1	(0.4)
Respiratory, thoracic and mediastinal disorders	**9**	**(3.3)**
Bronchiectasis	1	(0.4)
Cough	2	(0.7)
Dyspnoea	2	(0.7)
Haemoptysis	1	(0.4)
Pleural effusion	1	(0.4)
Pneumonitis	2	(0.7)
Pulmonary embolism	1	(0.4)

C Confidential

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）
001 試験パート B2+D（APaT 集団）（続き）

	Ipi-naïve 2 mg/kg Q3W		Ipi-naïve 10 mg/kg Q3W		Ipi-exposed 2 mg/kg Q3W		Ipi-exposed 10 mg/kg Q3W	
	n	(%)	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**2**	**(3.9)**	**1**	**(1.9)**	**2**	**(2.2)**	**2**	**(2.4)**
Neutrophilic dermatosis	0	(0.0)	0	(0.0)	1	(1.1)	0	(0.0)
Pruritus	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)
Rash	1	(2.0)	0	(0.0)	1	(1.1)	1	(1.2)
Rash generalised	0	(0.0)	1	(1.9)	0	(0.0)	0	(0.0)
Rash maculo-papular	1	(2.0)	0	(0.0)	0	(0.0)	1	(1.2)

付録 2.7.4-38 休薬に至った有害事象（いずれかの投与群で発現割合 0%超）
001 試験パート B2+D（APaT 集団）（続き）

	Total	
	n	(%)
Skin and subcutaneous tissue disorders	7	**(2.5)**
Neutrophilic dermatosis	1	(0.4)
Pruritus	1	(0.4)
Rash	3	(1.1)
Rash generalised	1	(0.4)
Rash maculo-papular	2	(0.7)

Every patient is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
MedDRA preferred terms 'Malignant neoplasm progression' not related to the drug is excluded.
(Database Cutoff Date: [redacted]

Data Source: [資料5.3.5.2.1.2: P001V02]

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Trial Number=3475-001, Site Number=0001, Subject ID=000284, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
000284	Treatment Cycle 7	134	Muscular weakness	1.61 Months	3		Y	Interrupted	Resolved
		148	Fatigue	1.15 Months	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0003, Subject ID=000286, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=64									
000286	Treatment Cycle 2	37	Diarrhoea	4 Weeks	2		Y	Interrupted	Resolved
		42	Abdominal pain	1.29 Weeks	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0008, Subject ID=000387, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=72									
000387	Treatment Cycle 1	23	Anaemia	5 Days	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000253, Gender=M, Race=White, Age=43 Years, Rel Day of Study Medication Discontinuance†=231									
000253	Safety Follow-up	251	Myalgia	Continuing	3		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000265, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=211									
000265	Treatment Cycle 8	170	Pneumonitis	1.86 Weeks	3	Y	Y	Interrupted	Resolved
		183	Pneumonitis	4 Weeks	2		N	Interrupted	Resolved
	Safety Follow-up	229	Pneumonitis	5.16 Months	2	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000371, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=317									
000371	Treatment Cycle 9	191	Blood bilirubin increased	Continuing	3		N	Interrupted	Not Resolved
		191	Hepatomegaly	Continuing	3		N	Interrupted	Not Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Trial Number=3475-001, Site Number=0010, Subject ID=000457, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=43									
000457	Treatment Cycle 2	26	Hyperuricaemia	Continuing	4	Y	N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000461, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									
000461	Treatment Cycle 6	121	Pruritus	1 Weeks	2		Y	Interrupted	Resolved
		121	Rash	1 Weeks	2		Y	Interrupted	Resolved
	Treatment Cycle 7	149	Rash	1.94 Months	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000289, Gender=M, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=129									
000289	Safety Follow-up	148	Metastases to central nervous system	5 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000291, Gender=M, Race=White, Age=73 Years, Rel Day of Study Medication Discontinuance†=44									
000291	Safety Follow-up	52	Hypophysitis	6 Days	4	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000315, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=									
000315	Treatment Cycle 18	369	Small intestinal obstruction	6 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000503, Gender=F, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=197									
000503	Treatment Cycle 4	70	Colitis	2.6 Months	2	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000475, Gender=M, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=1									
000475	Safety Follow-up	22	Blood bilirubin increased	Continuing	4		N	Interrupted	Not Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Trial Number=3475-001, Site Number=0016, Subject ID=000313, Gender=M, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=65									
000313	Treatment Cycle 4	65	Dyspnoea	2.1 Months	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=000326, Gender=F, Race=White, Age=72 Years, Rel Day of Study Medication Discontinuance†=22									
000326	Treatment Cycle 1	16	Skin infection	1.71 Months	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=000487, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=148									
000487	Treatment Cycle 4	64	Headache	2 Days	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=000469, Gender=F, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=239									
000469	Treatment Cycle 6	125	Constipation	3.43 Weeks	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000258, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=85									
000258	Safety Follow-up	86	Cognitive disorder	Continuing	1		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000303, Gender=M, Race=White, Age=39 Years, Rel Day of Study Medication Discontinuance†=421									
000303	Treatment Cycle 9	183	Arthralgia	1.29 Weeks	2		Y	Interrupted	Resolved
		183	Chills	1.29 Weeks	1		Y	Interrupted	Resolved
		183	Fatigue	1.29 Weeks	2		Y	Interrupted	Resolved
		183	Mucosal inflammation	1.29 Weeks	2		Y	Interrupted	Resolved
		183	Pyrexia	1.29 Weeks	1		Y	Interrupted	Resolved
		183	Rash	1.29 Weeks	2		Y	Interrupted	Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Trial Number=3475-001, Site Number=0019, Subject ID=000328, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=442									
000328	Treatment Cycle 12	234	Fatigue	3.57 Weeks	3		Y	Interrupted	Resolved
		251	Hyponatraemia	4.14 Weeks	4	Y	N	Interrupted	Resolved
	Treatment Cycle 19	393	Cough	3.71 Weeks	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000290, Gender=F, Race=White, Age=82 Years, Rel Day of Study Medication Discontinuance†=									
000290	Treatment Cycle 13	255	Bronchiectasis	1.38 Months	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000318, Gender=F, Race=White, Age=35 Years, Rel Day of Study Medication Discontinuance†=519									
000318	Treatment Cycle 3	63	Hepatitis	1.14 Weeks	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000322, Gender=M, Race=White, Age=34 Years, Rel Day of Study Medication Discontinuance†=									
000322	Treatment Cycle 1	13	Pleural effusion	6 Days	3	Y	N	Interrupted	Resolved
	Treatment Cycle 7	155	Alanine aminotransferase increased	1.14 Weeks	1		Y	Interrupted	Resolved
		155	Aspartate aminotransferase increased	1.14 Weeks	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000325, Gender=F, Race=White, Age=67 Years, Rel Day of Study Medication Discontinuance†=106									
000325	Treatment Cycle 1	6	Neutrophilic dermatosis	1.45 Months	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000501, Gender=M, Race=Asian, Age=59 Years, Rel Day of Study Medication Discontinuance†=1									
000501	Safety Follow-up	22	Alanine aminotransferase increased	3.71 Weeks	3		N	Interrupted	Resolved
		22	Aspartate aminotransferase increased	3.71 Weeks	3		N	Interrupted	Resolved
		22	Blood bilirubin increased	3.71 Weeks	3		N	Interrupted	Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 2 mg/kg Q3W									
Trial Number=3475-001, Site Number=0020, Subject ID=000544, Gender=F, Race=White, Age=69 Years, Rel Day of Study Medication Discontinuance†=239									
000544	Treatment Cycle 5	102	Cough	2.43 Months	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000547, Gender=M, Race=White, Age=49 Years, Rel Day of Study Medication Discontinuance†=									
000547	Treatment Cycle 10	195	Anaemia	1.1 Years	1		N	Interrupted	Resolved
	Treatment Cycle 21	466	Upper respiratory tract infection	1.14 Weeks	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000550, Gender=F, Race=White, Age=52 Years, Rel Day of Study Medication Discontinuance†=176									
000550	Treatment Cycle 7	131	Upper respiratory tract infection	2.86 Weeks	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000528, Gender=F, Race=White, Age=55 Years, Rel Day of Study Medication Discontinuance†=									
000528	Treatment Cycle 18	367	Pyrexia	6 Days	1	Y	N	Interrupted	Resolved
		367	Rash maculo-papular	3 Days	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000542, Gender=M, Race=White, Age=74 Years, Rel Day of Study Medication Discontinuance†=515									
000542	Treatment Cycle 19	401	Anaemia	3.86 Weeks	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0024, Subject ID=000459, Gender=M, Race=White, Age=51 Years, Rel Day of Study Medication Discontinuance†=246									
000459	Treatment Cycle 5	113	Catheter site infection	1.43 Weeks	3	Y	N	Interrupted	Resolved
	Treatment Cycle 7	161	Blood cortisol decreased	3 Days	2		Y	Interrupted	Resolved
		161	Blood testosterone decreased	Continuing	1		Y	Interrupted	Not Resolved
	Treatment Cycle 8	188	Dehydration	2 Days	3	Y	Y	Interrupted	Resolved
		188	Diarrhoea	2 Days	3	Y	Y	Interrupted	Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-001, Site Number=0001, Subject ID=000364, Gender=M, Race=White, Age=64 Years, Rel Day of Study Medication Discontinuance†=									
000364	Treatment Cycle 15	316	Cholecystitis	2 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0008, Subject ID=000403, Gender=F, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
000403	Treatment Cycle 10	211	Syncope	1 Days	3		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000267, Gender=M, Race=White, Age=66 Years, Rel Day of Study Medication Discontinuance†=									
000267	Treatment Cycle 25	524	Asthenia	Continuing	3	Y	Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000332, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=1									
000332	Safety Follow-up	20	Failure to thrive	1.43 Weeks	3	Y	N	Interrupted	Resolved
		30	Failure to thrive	Continuing	2		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000374, Gender=M, Race=White, Age=63 Years, Rel Day of Study Medication Discontinuance†=64									
000374	Safety Follow-up	85	Bilirubin conjugated increased	Continuing	4	Y	N	Interrupted	Not Resolved
		85	Blood bilirubin increased	Continuing	3		N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000452, Gender=F, Race=White, Age=33 Years, Rel Day of Study Medication Discontinuance†=233									
000452	Treatment Cycle 6	117	Rash generalised	4 Days	3	Y	N	Interrupted	Resolved
		121	Rash generalised	1.43 Weeks	2		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000479, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=526									
000479	Treatment Cycle 17	373	Atrial thrombosis	1.28 Months	4	Y	N	Interrupted	Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-001, Site Number=0010, Subject ID=000479, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=526									
000479	Treatment Cycle 21	502	Pulmonary embolism	5 Days	3	Y	N	Interrupted	Resolved
	Safety Follow-up	547	Haemoptysis	4 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0010, Subject ID=000497, Gender=M, Race=White, Age=57 Years, Rel Day of Study Medication Discontinuance†=									
000497	Treatment Cycle 22	453	Dyspnoea	3.29 Weeks	3		N	Interrupted	Resolved
		476	Dyspnoea	2.14 Weeks	1		N	Interrupted	Resolved
		483	Fatigue	1.14 Weeks	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000413, Gender=M, Race=White, Age=87 Years, Rel Day of Study Medication Discontinuance†=									
000413	Treatment Cycle 8	171	Alanine aminotransferase increased	6 Days	1		Y	Interrupted	Resolved
		171	Aspartate aminotransferase increased	3 Days	2		Y	Interrupted	Resolved
	Treatment Cycle 13	360	Adrenal insufficiency	4 Days	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0011, Subject ID=000535, Gender=F, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=429									
000535	Treatment Cycle 6	125	Cellulitis	1.86 Weeks	3	Y	N	Interrupted	Resolved
	Treatment Cycle 15	311	Eye irritation	1.58 Months	1		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0012, Subject ID=000305, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=									
000305	Treatment Cycle 13	271	Rash	3.14 Weeks	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000406, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=419									
000406	Treatment Cycle 1	22	Anaemia	Continuing	2		Y	Interrupted	Not Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-001, Site Number=0015, Subject ID=000406, Gender=M, Race=White, Age=83 Years, Rel Day of Study Medication Discontinuance†=419									
000406	Treatment Cycle 1	22	Dehydration	3.14 Weeks	1		Y	Interrupted	Resolved
		22	Diarrhoea	3.14 Weeks	2		Y	Interrupted	Resolved
	Treatment Cycle 8	155	Sepsis	1.14 Weeks	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000472, Gender=F, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
000472	Treatment Cycle 22	444	Nasopharyngitis	1.38 Months	1		N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000485, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=									
000485	Treatment Cycle 25	547	Ischaemic stroke	5 Days	4	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0015, Subject ID=000519, Gender=M, Race=White, Age=70 Years, Rel Day of Study Medication Discontinuance†=									
000519	Treatment Cycle 22	452	Gastrointestinal haemorrhage	Continuing	3	Y	N	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=000302, Gender=M, Race=White, Age=54 Years, Rel Day of Study Medication Discontinuance†=									
000302	Treatment Cycle 8	177	Blood bilirubin increased	1.14 Weeks	2		Y	Interrupted	Resolved
	Treatment Cycle 11	247	Blood bilirubin increased	2.14 Weeks	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0016, Subject ID=000327, Gender=F, Race=White, Age=48 Years, Rel Day of Study Medication Discontinuance†=358									
000327	Safety Follow-up	359	Arthritis	Continuing	2		Y	Interrupted	Not Resolved
Trial Number=3475-001, Site Number=0018, Subject ID=000474, Gender=F, Race=Asian, Age=61 Years, Rel Day of Study Medication Discontinuance†=113									
000474	Treatment Cycle 1	18	Nausea	4 Days	2		Y	Interrupted	Resolved

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-001, Site Number=0018, Subject ID=000474, Gender=F, Race=Asian, Age=61 Years, Rel Day of Study Medication Discontinuance†=113									
000474	Treatment Cycle 1	18	Vomiting	4 Days	2		Y	Interrupted	Resolved
		22	Anaemia	3.86 Weeks	3		N	Interrupted	Resolved
		22	Dehydration	5 Days	3	Y	N	Interrupted	Resolved
		22	Nausea	5 Days	3	Y	N	Interrupted	Resolved
		22	Vomiting	5 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000262, Gender=M, Race=White, Age=53 Years, Rel Day of Study Medication Discontinuance†=231									
000262	Treatment Cycle 8	161	Abdominal pain	2 Days	3	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000264, Gender=M, Race=White, Age=65 Years, Rel Day of Study Medication Discontinuance†=									
000264	Treatment Cycle 18	375	Diverticulitis	1.43 Weeks	3	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000278, Gender=F, Race=White, Age=29 Years, Rel Day of Study Medication Discontinuance†=									
000278	Treatment Cycle 10	191	Infusion related reaction	1 Days	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000297, Gender=M, Race=White, Age=76 Years, Rel Day of Study Medication Discontinuance†=211									
000297	Safety Follow-up	232	Rash maculo-papular	3.14 Weeks	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0019, Subject ID=000347, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									
000347	Treatment Cycle 8	154	Diarrhoea	2.1 Months	3		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000372, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=85									

C Confidential

付録 2.7.4-39 休薬に至った有害事象の一覧

001 試験パート B2+D（APaT 集団）（続き）

Subject ID	Epoch	Rel Day of Onset	Adverse Event	Duration	Toxicity Grade	Ser-ious	Related	Action Taken	Outcome
MK-3475 10 mg/kg Q3W									
Trial Number=3475-001, Site Number=0020, Subject ID=000372, Gender=F, Race=White, Age=62 Years, Rel Day of Study Medication Discontinuance†=85									
000372	Treatment Cycle 2	34	Tumour haemorrhage	4 Days	2	Y	N	Interrupted	Resolved
Trial Number=3475-001, Site Number=0020, Subject ID=000393, Gender=M, Race=White, Age=77 Years, Rel Day of Study Medication Discontinuance†=50									
000393	Treatment Cycle 1	17	Diarrhoea	1 Weeks	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000271, Gender=M, Race=White, Age=61 Years, Rel Day of Study Medication Discontinuance†=									
000271	Treatment Cycle 1	6	Pneumonitis	1.87 Months	2		Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000537, Gender=M, Race=White, Age=50 Years, Rel Day of Study Medication Discontinuance†=									
000537	Treatment Cycle 4	85	Tuberculosis	1.21 Years	1	Y	Y	Interrupted	Resolved
Trial Number=3475-001, Site Number=0021, Subject ID=000541, Gender=F, Race=White, Age=26 Years, Rel Day of Study Medication Discontinuance†=									
000541	Treatment Cycle 20	417	Viral infection	3.57 Weeks	2		N	Interrupted	Resolved

†Relative Day of Study Medication Discontinuance is defined as the day of the last recorded dose of study medication for the subject relative to the start of study medication.

Action Taken: None = DOSE NOT CHANGED, Reduced = DOSE REDUCED, Interrupted = DRUG INTERRUPTED, Discontinued = DRUG WITHDRAWN, Increased = DOSE INCREASED, N/A = NOT APPLICABLE.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Related: Investigator-assessed relationship of the adverse event to study medication.

Grades are based on NCI CTCAE version 4.0..

MedDRA preferred terms 'Malignant neoplasm progression' and 'Neoplasm progression' not related to the drug are excluded.

AEs were followed 30 days after last dose of study treatment

(Database Cutoff Date: [redacted].

Data Source: [資料5.3.5.2.1.2: P001V02]

C Confidential